9th International Conference of The Asian Clinical Oncology Society (ACOS)

Program

1.President Lecture	2.Key Note Lecture
3.Special Lecture	4.Educational Lecture
5.Memorial Program	6.Symposium
7.Workshop	8.Video Symposium
9.Luncheon Seminar	10.Mini-symposium
11.Mini-Video Symposium	12.Oral presentation
Poster Presentation with wine & cheese party at Royal Theater
Group A	Group B

Official schedule

Business meeting 　: August 24 from 16:30

President Banquet : August 24 from 18:10 ( request the invitation card)

Opening ceremony : August 25 from 8:15

General assembly : August 26 from 19:10 around Nagara-gawa river side
(all participant, including Cormorant fishing, etc )

Closing ceremony : August 27 from 16:30 Room 1 (all participant)

1. Closing Remarks
2. Cerebration for the winners of Young Investigator’s Award (YIA) and Kobayashi Foundation Award (KFA)
3. Flag move from Japan to Korea

Opening Ceremony ： Royal Theater

1. Flag parade by Patients’ Association of the breast, stoma, etc

2. Opening ceremony

3. Main theme presentation

9th ACOS Congress President Shigetoyo SAJI

4．Exhibition 9:30-10:00

KYOUGEN, a Japanese traditional performance by Motoya IZUMI

Congress Program

１．President Lecture

August 26　　Room 1 ：13:30-14:10

1. Yan SUN　（ACOS President, China）

Advances of studies in lung cancer in China

Chairman：Tetsuo Taguchi　（Honorary President）

August 26　　Room 1 ：14:10-14:50

2. Shigetoyo SAJI　（Congress President）

Recent advances of Japanese Clinical Oncology and our vision for cancer therapy

Chairman：Jacqueline Whang-Peng　(Taiwan）

2.Key Note Lecture

KN1.

August 25 Royal Theater ：10:10-11:00

Aimery de Gramont (France)

Recent advancement of adjuvant chemotherapy for colorectal cancer

Chairman：Kenichi SUGIHARA
Sponsored by YAKULT HONSHA CO,LTD

KN2．

August 25 Royal Theater ：11:00-11:50

Yusuke Nakamura

The present status and future perspectives of cancer vaccine

Chairman：Michio OGAWA
Sponsored by　Takeda Phamaceutical Company Limited

KN3.

August 26 Room 1 ：16:30-17:30

Ian Chau (United Kingdom)

The present and the future of Capecitabine

Chairman：Narikazu BOKU
Sponsored by CHUGAI PHARMACEUTICAL CO,LTD

KN4.

August 27 Room1 Theater ：10:40-11:40

Keisuke AIBA

The history of fluoropyrimidine compounds and S-1

Chairman：Yoshihiko MAEHARA
Sponsored by TAIHO PHARMACEUTICAL CO,LTD

3.Special Lecture

SL1.

August 25 Room 1 ：13:30-14:30

Tetsuhiko SHIRASAKA

Development history and concept of an oral anticancer agent S-1(TS-1®) Its clinical usefulness and future vistas

Chairman：Kosei HIRAKAWA
Sponsored by Fujii Tetsuro Foundation

SL2.

August 25 Room 3 14:00-15:00

Rainy Umbas　（Indonesia）

Multidiscipline approach in advanced urological cancer

Chairman：Soehartati GONDHOWIARDJO（Indonesia）

SL3.

August. 25　　　Room 8　：13:30-14:30

Seiji NAITO

Treatment of advanced renal cell carcinoma in the Era of molecular targeted agents

Chairman：Seiichiro OZONO
Sponsored by Pfizer Japan Inc.

SL4.

August 26 Room 1 ：14:50-15:50

Tetsuo NODA

Searching for novel molecular targets of cancer therapeutics using mouse models for human cancer

Chairman：Takashi SUGIMURA

SL5.

August 26　　Room 1 ：15:50-16:30

Hideo ISHIZUKA

Discovery of capecitabine and improvement of its efficacy

Chairman：Naohiro TOMITA
Sponsored by Japan Society for cancer chemotherapy

SL6.

August 26　Room 5 ：15:00-16:00

Malcolm Anthony Moore (UICC-ARO)

Cancer prevention and control in Asia in the coming Era

Chairman：Tomoyuki KITAGAWA

SL7.

August 26 Room ４：8:30-9:30

RHA Sun Young（Korea）

Why is the NCCN focusing Asian countries now ?

Chairman：Hideyuki AKAZA
Sponsored by Bayer Health Care

SL8.

August 26　　Room 5 ：9:15-10:00

Thangarajan Rajkumar （India）

Microarray studies on gastric cancer in south Indian patients

Chairman：Atsushi OCHIAI

SL9.

August 26　　Room 5 ：11:00-12:00

Keun-Young Yoo (Korea)

National cancer control program in Korea

Chairman：Morito MONDEN

SL10.

August 27　　Room 4 ：11:00-12:00

Masaki MORI

Cancer stem cell in solid cancer

Chairman：Eiichi TAHARA

4.Educational Lecture

EL1.

August 25 Room 3 ：17:30-18:30

Jun Ma (China)

The Chinese experience of acute promyelocytic leukemia treatment by arsenic trioxide

Chairman：Yoichi TAKAUE

EL2.

August 26　　Room2　：8:30-9:30

Hiroshi Shimada

Which should resection or continued chemotherapy for multiple bilobar liver metastases from colorectal cancer which have responded to chemotherapy be selected ?

Chairman：Takashi KANEMATSU

EL3.

August 26 Room 3 ：8:30-9:30

Masayuki IMAMURA

Treatment of pncreatic Endocrine Cell Tumores

Chairman：Hiroshi TAKAMI

EL4.

August 26 Room 5 ：8:30-9:15

Daldiyono Hardjodisastro (Indonesia)

Genetic epidemiology of the colorectal cancer, Report from Indonesia

Chairman：Junichi SAKAMOTO

EL5.

August 26 Room 3 ：14:00-15:00

Yasutsuna SASAKI

Ethnic difference in chemotherapeutic and molecular targeting agent for cancer

Chairman：Hisao ITO

EL6.

August 26　Room 5 ：18:00-19:00

Soundarapandian Kannan (India)

Development of therapeutic agents for non small cell lung carcinoma: Role of cPLA2α gene in anti-tumour drug targeting and drug ability

Chairman：Saburou SONE

EL7.

August 26 Room 6 8:30-9:30

Wataru YASUI

Novel diagnostic and therapeutic targets of gastrointestinal cancer identified by “Omics” study

Chairman：Masuo HOSOKAWA

EL8.

August 27 Room 3 ：13:30-14:30

Kojiro SHIMOZUMA　 and Takashi FUKUDA

Assessment of quality-of-live and health care economics in oncology

Chairman：Yasuo OHASHI
Sponsored by Nippon Kayaku Co,Ltd

EL9.

August 27 Room 5 ：8:30-9:15

Seiichi TAKENOSHITA

The clinical significance of preoperative chemoradiotherapy for advanced lower rectal cancer and the development of the molecular marker to predict the efficacy

Chairman：Takashi AIKOU

EL10.

August 27 Room5 ：11:00-12:00

John W. Gamel （USA）

Parametric survival analysis and adjuvant chemotherapy of breast cancer.

Chairman：Shunzo MAETANI
Sponsored by TENRI INSTITUE OF MEDICAL RESEARCH

EL11.

August 27　Room 6 ：　8:30-9:30

Sanjeev Misra　（India）

Current perspective in management of oral cancer in India

Chairman：Mamoru TSUKUDA

EL12.

August 27 Room 6 ：13:30-14:30

Quoc Thang Dang Huy (Viet Nam)

Diagnosis and treatment of mediastinal tumors

Chairman：Kota OKINAGA

5.Memorial Program

On time Symposium 1

August 25 Room 3 ：15:00-17:30

The present and the future of cancer managements in Asian countires ( with the commemorative book of the 9th ACOS 2010 in Gifu)　　

Chairmen：Kazuo TAJIMA、Antonio H Villalon (Philippine)
Commentator：Tetsuichiro MUTO

1) The present and the future in Japan： Tadao KAKIZOE
2) The present and the future in China： Yua-Kai Shi
3) Recent advance and prospects in Singapore ； Alex Yuang-Chi Chang
4) Present and future of cancer management in India： Sajeev Misra
5) The present and future of cancer managements in Korea： Yeul Hong Kim
6) The present and the future in Philippine： Antonio H Villalon
7) The present and the future in Taiwan： Tsang-Wu Liu

On time Symposium 2

August. 26 Room 3：16:00-18:30

The history and the mission of ACOS

Chairmen：Yuan-Kai Shi　(China)、Shigetoyo SAJI
Sponsored by Japan Society for cancer chemotherapy

Key Note Lecture Establishment, mission and course of the ACOS　：Tetsuo TAGUCHI
1) 8th Congress President Gracieux Fernando　（Filippine）
2) 9th Congress President Shigetoyo SAJI　（Japan）
3) The 6th and 10th ACOS conference in Seoul　（Korea）
4) Future vision 1 Jacqueline Whang-Peng　 (Taiwan),
5) Future vision 2 Sanjeev Misra　(India)
6) Regulation of ACOS Antonio H Villalon (Philippine)

Satellite Symposium 1

August 26 Room1 ：17:30-19:00

The new strategy of advanced gastric cancer treatment

Chairmen：Hiroshi FURUKAWA, Hideo BABA Commentator：Yung‐Jue Bang（Korea）
Sponsored by CHUGAI PHARMACEUTICAL CO,LTD

1) Chemotherapeutic strategy for HER2 positive gastric cancer Yung‐Jue Bang（Korea）
2) Chemotherapeutic strategy for HER2 negative gastric cancer) 　Hiroya TAKIUCHI
3) Peri-operative chemotherapy in gastric cancer 　　Ian Tat Man Chau　（United Kingdom）
4) The role of surgical treatment in stage IV gastric cancer 　　Atsushi NASHIMOTO

Satellite Symposium 2

August 26　　Room 2 ：16:30-19:00

Minimally Invasive Surgery for Gastric and Colorectal Cancer -What Experts Do and Where We go? -”

Chairmen：Kazuhiro YOSHIDA, Seon Hahn Kim (Korea) Commentator：Masaki KITAJIMA
Sponsored by Johnson & Johnson

1) Quality control and education of laparoscopic gastric gastric surgery Naoki HIKI
2) Robotic total gastrectomy　 Ichiro UYAMA
3) Gastric cancer surgery using robotic technology Woo Jin Hyung (Korea)
4) MIS for rectal cancer: robotic vs. laparoscopic Seon Hahn Kim (Korea)
5) Laparoscopy transverse colectomy with radical lymph node dissection Yosuke FUKUNAGA
6) Minimal invasive colorectal surgery : Should we do it because we can do it ? Woo-yong-Lee （Korea）

6.Symposium

S1.

August 25　　　Room 1 ：14:30-17:00

The present status and future perspectives of S-1 in gastric cancer - the present status in Japan and in other countries -

Chairman： Yuh SAKATA, Mitsuru SASAKO
Key Note Lecture Jaffer A. Ajani　（USA）
Sponsored by TAIHO PHARMACEUTICAL CO,LTD

1) The present status in Japan
The present status in Japan Clinical oncology : Wasaburou KOIZUMI
Neoadjuvant and adjuvant chemotherapy for gastric cancer : Kazuhiro YOSHIDA
2) The present status in Asian countries
Korea： Kang YK
China： Xu Rui-hua
Personalizing treatment of gastric cancer; A Singapore experience： Yong Wei-Peng
Clinical trials for S-1 in gastrointestinal cancer in Taiwan Li-Tzong Chen (Taiwan)

S2.

August 25　　Room 1 ：17:00-19:00

The present status of　HCC treatment in Asian countries

Chairman： Go WAKABAYASHI, Ronnie Poon (Hong Kong)
Sponsored by Bayer Health Care

1) Systemic resection for HCC Masakazu YAMAMOTO
2) Laparoscopic liver resection for hepatocellular caranoma 　Ho-Seong Han (Korea)
3) Radiofrequency ablation for hepatocellular carcinoma Shuichiro SHIINA
4) Living donor liver transplantation for HCC Shinji UEMOTO
5) Transcatheter arterial chemoembolization of primary liver cancer in challenging cases Subaru HASHIMOTO
6) Sorafenib; results from Asian clinical trial Ronnie Poon (Hong Kong)

S3.

August 25 Room 4 ：13:30-16:30

Novel treatment for NSCLC

Chairman： Norihiko IKEDA、 Sanghoon Jheon (Korea)
Key Note Lecture：Adequecy of lung cancer treatment 　 Harubumi KATO

1) Efficacy of 3-dimentional non-coplenar conformal radiation therapy for Stage Ⅰ non-smell cell lung cancer 　Katsuyuki KARASAWA
2) Photodynamic therapy Mitsuo USUDA
3) Current surgical strategy for small peripheral non-small cell lung cancer(NSCLC)Hisashi SAJI
4) Robot-assisted thoracic surgery for lung cancer Hyun-Sung Lee ( Korea）
5) Evaluation of chemotherapeutic target biomarkers in Non Small Cell Lung Cancer genotypes Jacqueline Ming Liu(Taiwan)

S4.

August 26, Room 1, 9:30-12:00

The present status and the future perspectives of Inter Group　Study in Asian countries

Chairman： Hiroya TAKIUCHI、Yoon-Koo Kang (Korea)
Sponsored by DAIICHI SANKYO CO, LTD

Key note lecture: Future directions of clinical trials in Asia Atsushi OHTSU
1) S-1 and Taxotere for advanced gastric cancer randomized Phase III trial : JACCRO GC-03（START) Hoon Kyo Kim ( St. Vincent Hospital Korea）
2) Development of clinical trial to gastric cancer surgery Toshimasa TSUJINAKA
3) SOS study: S-1 Optimal Schedule 3 weekly vs. 5 weekly Yoon-Koo Kang (Korea)
4) The goal of Intergroup Study in Asia: West Japan Oncology Group (WJOG) Kazuhiko NAKAGAWA
5) Collaboration between data centers of Korean and Japan in the intergroup trial JCOG0705/KGCA01 Haruhiko FUKUDA

S5.

August 26 Room 3 ：9:30-12:00

Breast cancer in Asian countries

Chairman： Koichi HIRATA Toshiaki SAEKI
Sponsored by CHUGAI PHARMACEUTICAL CO,LTD

1) Triple negative breast cancer in Korea- distinct biology with different impact of prognostic factors on survival Eun Sook Lee, M.D., Ph.D.　（Korea）
2)The ｐathological features of breast carcinoma in Asian women Takuya MORIYA
3) Measuring quality of care for breast cancer in Japan and effecting practice improvement Hirofumi MUKAI
4) Brest cancer in Japan Yasuyo SUZUKI

S6.

August 26 Room 4 ：9:30-12:00

Current topics in multimodal treatment for esophageal cancer

Chairman： Yuko KITAGAWA、　　Hideaki SHIMADA

1)A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage Ⅱ/Ⅲsquamous cell carcinoma of the thoracic esophagus (JCDG9907) Hiroyasu IGAKI
2) Neoadjuvant therapy for esophageal cancer Hideo BABA
3) Current progress in chemoradiotherapy for esophageal cancer in Japan Ken KATO
4) Role of salvage surgery in esophageal cancer treatment Yasuyuki SETO
5) Prediction of response for neo-adjuvant chemo-radiation　　Yuichiro DOKI
6) Novel multimodal treatment for resectable esophageal cancer :introduction of JCOG0909 Hiroya TAKEUCHI
7) Trends in multimodal treatment for esophageal cancer in Asia　Simon Law (Hong Kong)
8) Current topics of carbon-ion beam irradiation against esophageal cancer Hideaki SHIMADA

S7.

August 26 　Room 6 ：15:50-18:30

Chemo-radiotherapy: combination of advanced technology of radiation therapy and new drugs including molecular target agents

Chairman： Yasumasa NISHIMURA, Yasushi NAGATA
Sponsored by Varian

1) Combined modality treatment of stage III NSCLC: Novel approaches using IMRT, proton and molecular targeting therapy　 Chang Joe Y（USA）
2) Chemo-radiotherapy for locally advanced ＮＳCLC; Integration of EGFR-targeted agents　 Isamu OKAMOTO
3) Chemo-radiotherapy for locally advanced pancreatic cancer Satoaki NAKAMURA
4) Chemo-radiotherapy for head and neck cancer, Improving clinical benefits using IMRT and molecular target agent　　　　Takeshi KODAIRA　

S8.

August 27 Room1 ：13:30-16:30

Strategies and problems of Asian Traditional Medicine in cancer treatment

Chairman： Masaki KITAJIMA、 Leung Ping Chung (Hong Kong)
Commentator：Kenji WATANABE
Sponsored by TSUMURA &CO

Key Note Lecture： Kampo Medicine for cancer treatment in Japan　　Kenji WATANABE
1) Traditional medicine in China　Jian Ping Liu (China)
2) Research on cancer treatment using traditional medicine Leung Ping Chung(Hong Kong)
3) Outcome evaluation to advanced cancers treated with aRVS (allergen removed rhus vemiciflua) 　Won Cheol Choi, (Korea)
4) Juzentaihoto-induced inhibition of cancer metastasis – Establishment of molecular basis for Kampo medicine – Ikuo SAIKI
5) Role of Kampo medicine in cancer treatment Mitsuo SHIMADA
6) Effect of Goshajinkigan on peripheral neurotoxicity associated with oxaliplatin therapy for colorectal Cancer Toru KONO
7) Masahiko WATANABE

S9.

August 27 Room 3 ：8:30-10:50

Recent developments and future prospects of cancer treatments using the manner of Interventional Radiology

Chairman： Jae-Hyung　Park (Korea), Hironobu NAKAMURA
Sponsored by

1) Current trends in interventional radiological applications in oncologic practice in india Sanjiv Sharma (India)
2) Interventional oncology in China Ren-jie Yang (China)
3) Recent advancements and future prospects of interventional radiology for cancer treatment in Thailand Pongsuwan Pongdej (Thailand)
4) New interventional radiology techniques in the management of hepatocellular carcinoma: The SGH experience HoAu G Lo (Singapore)
5) Recent developments and future prospects of transarterial therapy for HCC Jae-HyungPark (Korea)
6) International oncology in Japan Yasuaki ARAI

S10.

August 27 Room 3 ：14:30-16:30

Palliative care for cancer patients and its challenges in Asia

Chairman： Cynthia Goh　(Singapore)、 Satoru TSUNETO
Sponsored by Nakono Foundation

1) Cynthia Goh (Singapore)
2) What benefits are achieved by oncologist engaging palliative care ? David Currow (Australia)
3) Palliative care for cancer patients in a multicultural context Ednin Hamzah (Malaysia)
4) Evolution of cancer care and palliative care in Japan. : shifting from the stage of disease to the intensity of suffering. Yasuo SHIMA

S11.

August 27 Room　5 ：13:30-16:00

Recent development of prostate cancer

Chairman： Tsuneharu MIKI、　Soehartati Gondhowiardjo

Key Note Lecture Soehartati Gondhowiardjo (Indonesia)
1) Epidemiology of prostate cancer : Shiro HINOTSU
2) Treatment strategies for CRPC based on hormone sensitivity Hiroyoshi　SUZUKI
3) Recent up-date on screening for prostate cancer　： Kazuto ITO
4) Primary androgen deprivation therapy in localized prostate cancer ； Atsushi MIZOKAMI
5) Optimization of surgical technique to preserve continence and erectile function after radical prostatectomy ：　Kazumi KAMOI
6) Radio therapy ：　Takashi MIZOWAKI

7.Workshop　

W1.

August 25 Room 4 ：16:30-18:30

Multidisciplinary approach in GIST treatment

Chairman： Hiroyuki KONNO, Han-Kwang Yang　（Korea）
Sponsored by Novartis Pharm KK

1) GIST clinical practice guidelines in Japan – Present and perspectives　 Toshirou NISHIDA
2) Surgical interventions for recurrent and metastatic GISTs 　Tatsuo KANDA
3) Current status of neoadjuvant trial against GIST Yukinori KUROKAWA
4) Korean standard of multidisciplinary approach in GIST-treatment. Han-Kwang Yang　（Korea）

W2.

August. 25 Room 5 ：13:30-16:00

Cancer pharmacogenomics in Asia

Chairman： Masahiko NISHIYAMA, Ji-Youn Han （Korea）
Sponsored by YAKULT HONSHA CO,LTD

Keynote lecture： Whole genome approaches to identifying pharmacogenomic markers in oncology　 M. Eileen Dolan （USA）
1) Pharmacogenomics in lung cancer: the latest states and progress in Taiwan (TBA).　John Wen-Cheng Chang (Taiwan.)
2) Pharmacogenomics and genetics in breast cancer Soo-Chin Lee (Singapore)
3) Irinotecan pharmacogenomics in Korean lung cancer patients. Ji-Youn Han (Korea)
4) The fruits of translational research and their application to clinical practice: genotype-based individualization of irinotecan chemotherapy Yuichi ANDO
5) Post-genome proteomic and metabolic analysis for pharmacological responses to anticancer agents. Yusuke TANIGAWARA

W3.

August 25 Room 5 ：16:00-18:45

The present status and the future perspective in cancer vaccine

Chairman： Hiroki YAMAUE, Chae-Ok Yun　（Korea）
Commentator：　Masaaki OKA
Sponsored by ：Fuso Pharmaceutical Industries,Ltd、OTSUKA PHARMACEUTICAL CO.,LTD、Shionogi & Co., Ltd.

Key Note Lecture： Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccines. Kyogo ITOH
1) Phase 1 study of multiple peptide vaccine therapy using novel cancer-testis antigen in treating patients with esophageal cancer 　Koji KONO　　
2) Glypican-3- derived peptide vaccine therapy for cancer Tetsuya NAKATSURA
3) Peptide vaccine therapy for patients with advanced pancreatic cancer- A clinical trial design from phase Ⅰ to phaseII/III for the development of therapeutic cancer vaccine- Motoki MIYAZAWA
4) Phase I clinical trial of WT1 peptide-based cancer vaccine in combination with gemcitabine for advanced pancreatic cancer Sumiyuki NISHIDA
5) PCancer peptide vaccine therapy for bladder cancer Wataru OBARA

W4.

August 26　Room 4 ：13:30-15:30

Therapeutic strategy in esophagogastric junction cancer

Chairman： Shoji NATSUGOE、 Simon Law （Hong Kong）

1) Pathological and characteristic features of esophago-gastric junctional (EGJ) cancer Tadakazu SHIMODA
2) Therapeutic strategy for adenocarcinoma of esophago-gastric junction Takaki YOSHIKAWA
3) Sumiya ISHIGAMI
4) The optional surgical approach for carcinoma of the gastro esophageal junction Toshihiro HIRAI
5) Management of gastroesophageal junction tumor Simon Law （Hong Kong.）
6) Thearpeutic strategy in esophagogastric junction cancer　　Hyuk-Joon Lee　（Korea）
7) Maria Burian　（Germany）

W5.

August　26　　Room 4　　：15:30-17:50

Diagnosis and treatment of IPMN of the pancreas

Chairman： Akimasa NAKAO, Dong Wook Choi （Korea）
Commentator: Yutaka ATOMI

Keynote Lecture: Better understanding of clinicopathological features of IPMN for better clinical managements Kyoichi　TAKAORI
1) Diagnosis of IPMN of the pancreas with pancreatic duct lavage cytology (tentative).　Jinkan SAI
2) Treatment guidelines for IPMN of the pancreas in Korea (tentative) Dong Wook Choi (Korea)
3) Surgical management of IPMN of the pancreas (tentative). Takashi HATORI

W6. [Open conference]

August 26 Room 5 ：　　13:30-16:00

The present status and future perspective in Team Oncology in Japan and Korea

Chairman： Seigo NAKAMURA、　Shigehira SAJI
Commentator：Naoto T Ueno (USA)、 Syuuichi KOJIMA(TBS)
Sponsored by GlaxoSmithKline

1) MD Anderson’s approach to team medicine/science　 Naoto T. Ueno (MD Anderson CC).
2) Problems and perspectives on multidisciplinary care in Japan. Chikako SHIMIZU
3) The role of advanced oncology nurse for team oncology in Korea Ji-Hyun Sung (Korea)
4) Development of team approach at a breast center: Comprehensive care approach for hereditary breast cancer Hiroko KOMATSU
5) The role of pharmacist for Team Oncology in Korea Ji-Seon Choi (Korea)
6) The role of pharmacist for Team Oncology in Japan Hirotoshi IIHARA

W7. [Open conference]

August 26 Room 5 ：　 16:00-18:00

Education systems of specialists for nurses and pharmacists in oncology

Chairman： Ryosuke TSUCHIYA, Keiichi YOSHINO、Reiko SATHO RN
Sponsored by Japanese Foundation for Multidisciplinary Treatment of Cancer

1) Education systemｓ for cancer specialist in Japan 　Gen INOUE （Ministry of Education, Culture, Sports, Science and Technology）
2) Interim report of the basic plan to promote cancer control programs. Shiho TAKAOKA（Cancer Control Office, Health Service Bureau　Ministry of Health, Labour and Welfare）
3) The outcome of oncology certified nurse specialist training as program at master of science in nursing Kazuko ONISHI RN
4) Oncology nursing in Korea Jae-Jin Cho, RN （Korea）
5) Oncology nursing in CHINA Beiwen wu. RN (China)

W8.

August 26 Room 6 ：9:30-12:00

Temozomomide in Asia

Chairman： Kazuhiko SUGIYAMA, Do Hyun Nam（Korea）
Sponsored by Schering-Plough

Key Note Lecture : Present and future role of temozolomide to cure for malignant glioma Do Hyun Nam （Korea）
1) The efficacy of temozolomide chemotherapy for glioblastoma -from the experiences of consecutive 151 patients treated in a single institute- Hirofumi HIRANO
2) Clinical significance of temozolomide therapy in patients with glioblastoma Hirohito YANO,
3) A Multicenter Phase I Trial of Combination Therapy with Interferon-β and Temozolomide for High-grade Gliomas (INTEGRA study) : The final report Toshihiko WAKABAYASHI
4) Safety of radiotherapy plus concomitant and prolonged-term adjuvant temozolomide for glioblastoma in Japan – A Japanese multicenter phase II clinical study – Kazuhiko SUGIYAMA
5) Present and Future role of Temozolomide to a Cure for Malignant Glioma Do Hyun Nam (Korea)

W9.

August 26 Room 7 ：10:00-12:00

Current state and problem for childhood cancers in Asia

Chairmen： Yasuhide MORIKAWA、Devendra Gupta (India)
Sponsored by CHUGAI PHARMACEUTICAL CO,LTD

1) Current status of diagnosis and treatment of childhood cancers in India (tentative) Devendra Gupta (India)
2) The current status of pediatric cancers in Taiwan Wen-Ming Hsu （Taiwan）
3) Central pathology review system in pediatric cancers in Japan Atsuko NAKAZAWA
4) Preliminary results of the Japan Rhabdomyosarcoma study group trial using central pathology review and chimeric gene analysis. Yasuhide MORIKAWA
5) Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS Group　Takaharu OUE (JWiTS Group)
General comments：　The Asian Network of Childhood Cancers Tumor Banks for cure of Sick Children Akira NAKAGAWARA

W10.

August 27 Room 2 ：9 :50-12:00

Global and Asian consensus in breast cancer managements

Chairman： Masakazu TOI, CHEONG Wing Chow (Hong Kong)
Sponsored by Sanofi-aventis

1) Japanese consensus viewing through guidelines Tadashi IKEDA
2) The metastatsis mechanism of breast cancer　　Zhi-Ming Shao （China）
3) Axillary management of early breast cancer Dong-Young Noh (Korea)
4) pharmacotherapy for the breast cancer Chiun-Sheng Huang (Taiwan）

W11.

August 27 Room 4 ：8:30-11:00

Psychological distress and bad news communication in East Asia

Chairman： Yosuke UCHITOMI, Kazuhiro YOSHIUCHI

1) Distress management and communication skills training for oncologists in Japan: Kazuhiro YOSHIUCHI,
2) Distress management and communication skills training in oncology – Korean experiences. Jong-Heun Kim　（Korea）
3) Demoralization syndrome of cancer patients and communication skill training for physicians in Taiwan. Chun-Kai Fang （Taiwan）
4) Basic research on psychological distress and bad news communication. Yosuke UCHITOMI

W12.

August 27 Room 5：9:15-11:00

Management and problems in relieving cancer pain

Chairpersons： MR Rajagopal， Yuji SAITO

1) MR Rajagopal (India)
2) Management and problems in relieving cancer pain from an anesthsiological point of view Toshihiko NAKATANI
3) Clinical differences between opioids in cancer pain management Etsuko ARUGA

W13.

August 27 Room 6 ：9:30-12:00

Nasopharyngeal and oral cancer management in Asian countries

Chairman： Toshiyuki SHIBATA, Ryuichi HAYASHI
Commentator：Hiroshi KOBAYASHI
Sponsored by Han-Kaigi

1) High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. Yoshihiko ABIKO
2) Oral cancer chemoprevention in Sri Lanka Itsuo CHIBA
3) Nasolabial flap reconstruction of oral cavity defects: a report of 15 cases.Han Thi Van Thanh (Viet Nam.)
4) Mandibular reconstruction with fibula flap after segmental mandibulectomy for ameloblastoma 　Nguyen Thanh Thai (Viet Nam)
5) Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas 　　Nguyen Khanh Long (Viet Nam)

8.Video Symposium

VS1.

August 25 Room 2 ：13:30-15:45

Laparoscopy assisted gastrectomy in the present and the future
“ Tips and Pitfall for the Gastrectomy procedure: how we are doing”

Chairman： Ichirou UYAMA、 Hang-Kwang Yang　（Korea）
Sponsored by Olympus Medical System Corp

１） The outmost layer of the autonomic nerve: The critical layer for the secure and precise nodal dissection in laparoscopic and robotic gastrectomy for gastric cancer. Seiji SATO　　　　　　　　　　
２） Current status of laparoscopic gastrectomy in Korea . Sang-UK Han　（Korea）　
３） Enders Ng 　(Hong Kong)
４）　Hybrid mini-invasive surgery for gastric cancer　　Ming-Tsan Lin　（Taiwan）
５） Laparoscopic total gastrectomy with esophagojejunostomy using liner stapling devices. Eishi NAGAI　

VS2.

August 25　　Room 2 ：15:45-18:00

Laparoscopic rectum cancer surgery

Chairman： Mitsugu SEKIMOTO、　Michael Li （Hong Kong）
Commentator ：　Fumio KONISHI
Sponsored by COVIDIEN JAPAN

１） Standardization of laparoscopic low anterior resection. Akiyoshi KANAZAWA
2)　Laparoscopic rectal cancer surgery based on fascial anatomy Yusuke KINUGASA
3)　Laparoscopic D3　lymph node dissection with left colic artery preservation for rectal cancer Kazuki UEDA　
4)　Laparoscopic intersphincteric resection; short term outcome Cheol H Kim （Korea）
5)　Ke Dao-wei （Taiwan）
6) Advances in functional preservation in colorectal surgery Michael Li（Hong Kong）

VS3.

August 26　　Room 2 ：14:30-16:30

The latest developments in gastric and colon cancer surgery -New devices for safe and secure lymph nodes dissection and reconstruction-”

Chairman： Chang Sik Yu (Korea), Mitsuru SASAKO
Sponsored by Johnson & Johnson

Keynote lecture :　Application of new devices for lymph node dissection 　Masanori TERASHIMA
1) Innovation in gastric cancer surgery. Sung Hoon Noh (Korea)
2) New device for SAFO & secure lymph node dissection and reconstruction Jaideep Raj RAO (Singapore)
3) Open rectum cancer ; lateral pelvic lymph node dissection . Hidero YANO
4) Lymph node distribution and pattern of metastases in the mesorectum following TME using the modified fat clearing technique. 　Jin Gu (China)

9.Luncheon Seminar　

LS1.

August. 25　　Room　１　：12:00-13:30

Advances in therapy of gastric cancer
Jafferhusen A. Ajani （USA）

Chairman： Masashi FUJII
Commentator: Toshifusa　NAKAJIMA
Sponsored by TAIHO PHARMACEUTICAL CO.,LTD

LS2.[VIDEO]

August 25　　Room　2　：12:00-13:30

Minimally invasive lung cancer surgery
Makoto ODA and Jheon Sanghoon（Korea）

Chairman： Hiroshi DATE
Sponsored by COVIDIEN JAPAN

LS3.[Luncheon Seminar and Symposium]

August 25　　Room 3　　： 12:00-14:00

1) 12:00-12:05 Opening：Academician Jacqueline Whang-Peng (Taiwan)
2) 12:05-12:35 The recent advances in the treatment of locally advanced and metastatic head and neck cancer Taiwan CGMH Experience　　Hong-Ming Wang （Taiwan）
3) 12:35-13:05 Anti-angiogenic therapy for advanced hepatocellular carcinoma: the potential role of metronomic chemotherapy Chiun Hsu (Taiwan)
4) 13:05-13:35 Liposome technology review and clinical application of Lipo-Dox in different types of cancers　　Ruey-Kuen Hsieh (Taiwan)
5) 13:35-13:50 Panel discussion　All
6) 13:50-14:00 Closing　Academician Jacqueline Whang-Peng

10.Mini-symposium

MS1.Cancer immunotherapy

August. 25 Room 6 14:30 - 15:30

Chairmen: Kiyotaka OKUNO Hideaki YAMANA

M-1 Immunological and clinical responses of vaccination with colorectal cancer- specific peptides in combination with UFT/LV in advanced colorectal cancer
Fumiaki Sugiura( Japan)
M-2 Phase 1 trial of Wilms’ tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer
Yuriko M. Hoshi( Japan)
M-3 Preoperative intratumoral ijection of immature dendritic cells with OK-432 for the resectable pancreatic cancer
Akira Kenjo( Japan)
M-4 Color-coded in vivo imaging of tumor stem cells and co-implanted non-stem cancer cells
Atsushi Suetsugu( USA)
M-5 High-dose chemotherapy plus autologous stem-cell transplantation as a onsolidation treatment for poor risk and relapsed germ-cell tumors; a pilot study
Hideki Tsujimura( Japan)

MS2.Recent advances in Hematological malignancy 1

August. 25 Room 6 15:30 - 16:30

Chairmen: Lin Gui (China) Hisashi TSURUMI

M-6 A multicentre Phase II feasibility study evaluating Gemcitabine/Vinorelbine/ prednisolone combination chemotherapy in relapsed/refractory Hodgkin’s disease
Naeem Naqi( Pakistan)
M-7 High-dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma: Transplantation in the complete remission to the first-line chemotherapy may be the best timing
Lin Gui( China)
M-8 Impacts of autologous peripheral blood stem-cell mobilization in Chinese patients with lymphoma
Xiaohong Han( China)
M-9 Histone deacetylase inhibitor chidamide induces apoptosis and interacts with rituximab against mantle cell lymphoma
Bo Li( China)
M-10 Thalidomide and liposomal doxorubicin inhibit human osteoclastogenesis
Yu-Jen Chen　（Taiwan）

MS3.Recent advances in Hematological malignancy 2

August. 25 Room 6 16:30 - 17:20

Chairmen: Jun Ma (China) Zeba Aziz (Pakistan)

M-11 Combined treatment with rituximab enhances antitumor effect of Histone deacetylase inhibitor vorinostat on mantle cell lymphoma in vitro and in vivo
Wei Shi( China)
M-12 Effects of combining HHGV678 and imatinib in Bcr-Abl+ chronic myelogenous leukemia cell lines
Lin Qin( China)
M-13 Growth inhibition of arsenic trioxide in Bcr-Abl mutant cells and the potential mechanism
Xiaodan Wang( China)
M-14 Assessment of quality of life with imatinib mesylate in chronic phase chronic myeloid leukemia
Javaid Iqbal( Pakistan)

MS4.Recent advances in urogenital cancer

August. 25 Room 8 14:30 - 16:00

Chairmen: Mamoru KUSAKA Yoichi MIZUTANI

M-15 PSA after definitive radio-monotherapy by IMRT for clinical localized prostate cancer
Yasuyuki Nishida( Japan)
M-16 Temsirolimus induced non-infectious pneumonitis in metastatic renal cell Carcinoma (YIA)
Hyang K Kim( Korea)
M-17 Significance of TS, TK and OPRT activities in bladder cancer
Yoichi Mizutani( Japan)
M-18 Genome-wide association study identifies five new susceptibility loci for prostate cancer in Japanese population (YIA)
Ryo Takata( Japan)
M-19 Relationship between prostate-specific antigen and obesity: analysis of a large cohort of TOYOTA Motor Corporation employees (YIA)
Yasuaki Kubota( Japan)
M-20 Carcinoma of urinary bladder treated with radical cystectomy in Nepal (YIA)
Prakash R. Neupane( Nepal)
M-21 WT1 alterations in nephroblastomas and the genotype-phenotype correlation in Japan.
Hajime Okita (Japan)

MS5.Cancer of the stomach

August. 26 Room 1 8:30 - 9:30

Chairmen: Yoshitaka YAMAMURA Mikihito NAKAMORI

M-22 Phase II Study of biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
Chikara Kunisaki( Japan)
M-23 Usefulness of staging laparoscopy and induction chemotherapy with S-1 plus Docetaxel for advanced gastric cancer
Shiro Iwagami( Japan)
M-24 Updated results of a phase II trial of postoperative S-1 monotherapy for CEA mRNA (+) gastric cancer patients.
Seiji Ito( Japan)
M-25 Tesetaxel, a novel oral treatment for advanced gastric cancer: Dose-ranging study of two schedules (weekly vs. every 3 weeks)
Muralidhar Beeram( USA)
M-26 Postoperative management after hepatectomy for metastatic liver gastrointestinal stromal tumors based on genetic analysis.
Hirotoshi Kikuchi( Japan)

MS6.Cancer of the liver

August. 26 Room 2 9:30 - 10:45

Chairmen: Tetsuo OHOTA Masaru MIYAZAKI Kannika Phornphutkul (Thailand)

M-27 The primary investigation of Glypican 3 expression in well differentiated hepatocellular carcinoma
I-Pei Chen( Japan)
M-28 Prognostic implications of serum alpha-fetoprotein response after chemotherapy of hepatoblastoma
Jong Jin Seo( Korea)
M-29 IGFBP 7 alters the sensitivity to IFN-based combination therapy in hepatocellular carcinoma cells (YIA)
Yoshito Tomimaru( Japan)
M-30 The correlation between cancer stem like cells and epigenetic alteration in intrahepatic cholangiocarcinoma (YIA)
Yu Saito( Japan)
M-31 Clinico-pathologic features of hepatocellular carcinoma patients survived without recurrence for more than 5 years after surgery
Toshiya Ochiai( Japan)
M-32 Thalidomide-based Multidisciplinary Treatment for Patients with Advanced Hepatocellular Carcinoma: A Retrospective Analysis
Yang-Yuan Chen　（Taiwan）

MS7.Colorectal cancer with liver metastasis

August. 26 Room 2 10:45 - 12:00

Chairmen: Koutarou MAEDA Toru BEPPU

M-33 New development for the treatment of advanced and / or metastatic colorectal cancer patients -Positioning of IRIS therapy and tips for treatment continuity-
Naoko Hayashi( Japan)
M-34 Phase II study of FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan
Takao Takahashi(Japan )
M-35 New strategy for local recurrence of rectal cancer
Keiichi Takahashi( Japan)
M-36 A new strategy for the treatment of liver metastasis of colorectal cancer
Toshiaki Ishikawa( Japan)
M-37 Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer
Yuji Miyamoto( Japan)
M-38 Strategy for synchronous and multiple liver metastasis
Shinji Osada( Japan)

MS8.Recent advances in pancreatic cancer

August. 26 Room 4 17:50 - 18:50

Chairmen: Satoshi KONDO Shuji ISAJI

M-39 Plasma pharmacokinetics of gemcitabine and 5-fluorouracil in combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer
Bunzo Nakata( Japan)
M-40 Proposal of vertical gastrojejunostomy and duct-to-mucosa pancreato-jejunostomy with ometal wrapping after pylorus-preserving pancreaticoduodenectomy for IPMN
Tatsuo Shimura( Japan)
M-41 Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduced hypoxia in tumors (YIA)
Yusuke Mizukami( Japan)
M-42 Outcome of pancreaticoduodenectomy in Tribhuvan University Teaching Hospital, Kathmandu Nepal (YIA)
Paleswan Joshi Lakhey( Nepal)
M-43 Non-functioning pancreatic endocrine tumor: A case report
Nobuhiro Yoshimoto( Japan)

MS9.Cancer Research of the lung 1

August. 26 Room 6 13:50 - 14:50

Chairmen: Naoki WATANABE AMM Shariful Alam (Bangladesh)

M-44 EGFR mutation associates with sensitivity for anticancer agents in lung cancer
Tatsuya Yoshimasu( Japan)
M-45 EGFR mutation and P-EGFR expression in resected non-small cell lung cancer
Wei Liu( China)
M-46 SALL4 expression is essential for cancer cell proliferation and is elevated in the early stages of lung cancer
Daisuke Kobayashi( Japan)
M-47 Safety and efficacy of Gefitinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A single institution study (Nepal).(YIA)
Sudip Shrestha( Nepal)
M-48 Female gender as a prognostic factor in non-small cell lung cancer
Haruhiko Nakamura( Japan)

MS10.Cancer Therapy of the lung 2

August. 26 Room 6 14:50 - 15:50

Chairmen: Haruhiko NAKAMURA Anjani Kumar Sharma (Nepal)

M-49 Endobronchial ultrasonography using the guide sheath for peripheral lung cancer
Noriaki Kurimoto( Japan)
M-50 Magnetic resonance imaging in peripheral lung adenocarcinoma: correlation with histopathological features
Ryota Tanaka( Japan)
M-51 Thoracoscopic lobectomy in lung cancer: analysis in relation to compliance of adjuvant chemotherapy
Jin Gu Lee( Korea)
M-52 Importance of the histological type definition of lung cancer
Hiroyuki Miura( Japan)
M-53 Stereotactic body radiotherapy for non-small cell lung cancer: Kyoto University Experience
Yukinori Matsuo( Japan)

MS11.TS-1 for cancer of the stomach

August. 27 Room 1 9:40 - 10:40

Chairmen: Yasuhiro KODERA Toshiharu YAMAGUCHI

M-54 Postoperative adjuvant chemotherapy of oral S-1 has limited survival benefits for scirrhous gastric cancer patients - future direction
Mikihito Nakamori( Japan)
M-55 Long term surveillance of CY1 gastric cancer patients after radical gastrectomy followed by S-1 chemotherapy (CCOG0301)
Norifumi Ohashi( Japan)
M-56 Retrospective study of the patients with unresectable gastric cancer (UNGC) who underwent a gastrectomy after receiving S-1 or S-1 combination chemotherapy (S-1+α)
Kazuma Kobayashi( Japan)
M-57 Feasibility study of adjuvant therapy with S-1 plus cisplatin in gastric cancer
Daisuke Takahari( Japan)
M-58 Feasibility of S-1/CDDP as postoperative chemotherapy for gastric cancer
Yasuhiro Kodera( Japan)

MS12.Cancer research of the breast

August. 27 Room 2 8:30 - 9:45

Chairmen: Shin-ichi HAYASHI Hirotaka IWASE

M-59 Clinicopathological and biological features of triple negative breast cancer in Japan
Yutaka Yamamoto( Japan)
M-60 Protein profiling predicts the response to anthracycline and taxanes based neo- adjuvant chemotherapy in breast cancer
Shu Wang( China)
M-61 Different impact of loss of heterozygosity at BRCA1 and BRCA2 loci on breast cancer prognosis by the subtype approximated by estrogen receptor, progesterone receptor and HER2
Satoko Okada( Japan)
M-62 The breast cancer risk estimated by NSABP/Gail model in Japan
TOSHIAKI SAEKI( Japan)
M-63 Quantitative evaluation of transcriptional activity of estrogen receptor and expression of novel estrogen responsive genes for individualization of breast cancer
Tatsuyuki Gohno( Japan)
M-64 HER2/neu status in human breast cancer: Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC)
Xiaohong Han( China)

MS13.Cancer of the esophagus

August. 27 Room 3 10:50 - 12:00

Chairmen: Hisahiro MATSUBARA Hiroyuki KUWANO

M-65 Efficacy and safety of induction chemotherapy with Docetaxel/Cisplatin/5-FU for patients with node-positive esophageal cancer
Masayuki Watanabe( Japan)
M-66 Feasibility study of preoperative docetaxel (D), cisplatin (C), and fluorouracil (F) in esophageal cancer.
Chihiro Kondo( Japan)
M-67 A study on surgical procedures for gastric cancer with more than 3cm tumor extension to the esophagus based on the clinicopathological and prognostic findings
Ichiro Nakamura( Japan)
M-68 Factors to predict the mediastinal LN metastasis in patients with carcinoma of esophagogastric junction
Shinichi Tsuwano( Japan)
M-69 Clinicopathological findings for adenocarcinoma of the esophagogastric junction
Masaharu Higashida( Japan)
M-70 Evaluation of the seventh TNM classification system in esophageal cancer patients treated with definitive chemoradiotherapy
Motoo Nomura( Japan)

MS14.Chemotherapy for the colorectal cancer

August. 27 Room 4 13:30 - 14:30

Chairmen: Hideyuki ISHIDA Koh MIURA

M-71 A randomized phase II study of modified OPTIMOX1 or FOLFOX in advanced colorectal cancer : an interim report
Hideya Kashihara( Japan)
M-72 FOLFOX4 is less effective for the patients with hypoalbuminemia or immune impairment
Masahiko Shibata( Japan)
M-73 A multicenter phase II study of second-line FOLFIRI plus Cetuximab with KRAS wild type gene in metastatic CRC patients (FLIER)
Kenji Amagai( Japan)
M-74 KRAS/BRAF mutations and PTEN/p-AKT expression as predictive markers for cetuximab in Japanese colorectal cancer patients
Tomoya Yokota( Japan)
M-75 Genotype subset selection of multi-UGT1As polymorphisms can predict severe neutropenia and tumour responses of metastatic CRC patients received FOLFIRI regimen
Shoichi Hazama( Japan)

MS15.Cancer of the liver and liver transplantation

August. 27 Room 4 14:30 - 15:45

Chairmen: Mitsuo SHIMADA Hidetoshi MATSUNAMI

M-76 Endoscopic Surgery for Hepatocellular Carcinoma –Assessment of Ten-year Survival
Toru Beppu( Japan)
M-77 Thoracoscopic local ablation for the treatment of hepatocellular carcinoma
Takatoshi Ishiko( Japan)
M-78 Efficacy of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma
Takebumi Usui( Japan)
M-79 Timing of salvage transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Up-to-7 criteria
Tohru Utsunomiya( Japan)
M-80 Usefulness of Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma
Toshimi Kaido( Japan)
M-81 Chemotherapy for HCC after liver transplantation
Hidetoshi Matsunami( Japan)

MS16.Recent advances in gynecological cancer

August. 27 Room 6 14:30 - 16:00

Chairmen: Toru SUGIYAMA Lalit Kumar (India)

M-82 A primary squamous cell carcinoma of fallopian tube accompanied with gastric metaplasia of female genital tract-case report and review
Tsukasa Baba( Japan)
M-83 Cervical cancer prevention in Jakarta-Indonesia, see and treat model
Laila Nuranna( Indonesia)
M-84 Oct4 expression in immature teratoma of ovary: immunohistochemical analysis of 18 cases
Kaoru Abiko( Japan)
M-85 Correlation between chief complaint and staging among cervical cancer patients in Cipto Mangunkusumo Hospital during 2006-2007
Laila Nuranna( Indonesia)
M-86 Implication of metalloprotease-disintegrin protein family (ADAMs & ADAMTSs) in carcinogenesis and cancer progression of uterine cervix
Mohammed N. Shaker( Japan)
M-87 Clinicopathological predictive factors of persistence or recurrence after conization for cervical intraepithelial neoplasia (YIA)
Kouichiro Kawano( Japan)
M-88 Clinicopathological factors indicating pelvic lymph nodes metastasis in early stage cervical carcinoma (YIA)
Sarita Ghimire( Nepal)

11.Mini-Video Symposium

MVS1. Colorectal

August. 26 Room 2 13:30 - 14:30

Chairmen: Masazumi OKAJIMA Toru TANI

MV-1 Laparoscopic surgery after preoperative chemoradiation for T3 and T4 rectal cancer
Tomohiko Miyatani( Japan)
MV-2 Laparoscopic total mesorectal excision for middle and lower rectal cancer: experience of 112 cases.
Gang Li( China)
MV-3 Single incision laparoscopic surgery (SILS) with colon lifting method for colorectal cancer of early stage
Shoichi Fujii( Japan)
MV-4 Laparoscopy assisted hepatectomy; our techniques and results
Takashi Motomura( Japan)

MVS2. Esophagus

August. 27 Room 1 8:30 - 9:40

Chairmen: Hiroyasu MAKUUCHI Yasushi TOH

MV-5 Prevalence of thoracoscopic radical esophagectomy by direct instruction
Itasu Ninomiya( Japan)
MV-6 Video-assisted thoracoscopic esophagectomy with extended mediastinal lymph- adenectomy using a newly developed hybrid position
Hiroya Takeuchi( Japan)
MV-7 Surgical outcome of video-assisted thoracoscopic surgery for esophageal
Chikara Kunisaki( Japan)
MV-8 A triangulating stapling technique for the cervical esophagogastric anastomosis after esophagectomy
Yasushi Toh( Japan)
MV-9 A safe technique for esophageal replacement using the whole stomach while preserving the vessel network in the stomach
Hideo Matsumoto( Japan)

MVS3. Stomach

August. 27 Room 2 13:30 - 14:50

Chairmen: Motoki Ninomiya Chikara KUNISAKI

MV-10 The benefits of the standardization in laparoscopic gastrectomy
Masanori Tokunaga( Japan)
MV-11 Surgical risk factors and the measures for laparoscopy assisted gastrectomy (LAG)
Nobuhiro Kurita( Japan)
MV-12 Lymph nodes dissection with setting starting and end point and the “bottom” of regional lymph nodes station for advanced gastric cancer
Motoki Ninomiya( Japan)
MV-13 The current state of laparoscopic gastrectomy in Saga University
Kiichiro Kobayashi( Japan)
MV-14 The application of Liga-Sure precise® to the lymph node dissection in gastric cancer surgery.
Shinichi Kinami( Japan)
MV-15 The techniques of lymph node dissection for advanced gastric cancer in laparoscopic gastrectomy: The secure and feasible method considering laparoscopy-enhanced surgical anatomy
Osamu Ikeda( Japan)

MVS4. Stomach and breast

August. 27 Room 2 14:50 - 16:00

Chairmen: Kazuki INABA Sadao AMANO

MV-16 Influence of overweight on robot assisted total gastrectomy for gastric cancer
Kazuki Inaba( Korea)
MV-17 Minimally invasive procedures about Robotec Surgery: Pancreatic resection using da Vinc system
Masahiro Ito( Japan)
MV-18 Video-assisted breast surgery is for the benefit of Asian breast cancer patients.
Koji Yamashita( Japan)
MV-19 Clinical usefulness of sentinel lymph node biopsy under local anesthesia using SPECT-CT fusion imaging in breast cancerv
Hirotaka Iwase( Japan)
MV-20 Novel molecular method OSNA for rapid diagnosis of sentinel lymph node biopsy in breast cancer.
Nariaki Matsuura( Japan)

12.Oral presentation

O1. Gastric Cancer 1 (Pathological significance)

August. 25 Room 6 17:35 - 18:35

Chairmen: Michio KAMINISHI Norihito WADA

O-1 Prognostic impact of microscopic positive margin in gastric cancer patients
Tomoyuki Nagata( Japan)
O-2 Gastric cancer perforation: Report of 22 cases (YIA)
Bishnu P Kandel( Nepal)
O-3 Clinical evaluation of remnant gastric cancer following distal gastrectomy
Sayuri Nishino( Japan)
O-4 Evaluation of the seventh edition of the TNM classification of gastric cancer –from the viewpoint of survival-
Etsuro Bando( Japan)
O-5 Clinical evaluation of JCGC and TNM Staging on multidetector-row computed tomography in preoperative nodal Staging of gastric cancer (YIA)
Shuhei Komatsu( Japan)
O-6 Surgical management of gastric cancer in young adults (YIA)
Bikal Ghimire( Nepal)

O2. Biomarker for cancer

August. 25 Room 7 13:30 - 14:50

Chairmen: Yasutsuna SASAKI Nariaki MATSUURA

O-7 Expression of carbonic anhydrase IX is predominantly regulated by site-specific DNA methylation rather than hypoxia in gastric cancer and affects the gastric carcinogenesis
Jun Nakamura( Japan)
O-8 Thrombospondin-1 expression enhances antitumoral efficacy of oncolytic Herpes Simplex for gastric cancer (YIA)
Toshiaki Tsuji( Japan)
O-9 Association of K-ras and B-raf mutation status with the treatment effect of Cetuximab for metastatic colorectal cancer
Naoki Okumura(Japan )
O-10 CEACAM1 and CD133 expressing Spheroid with hollow at the invasion front of colorectal cancer -Novel metastatic and tumor initiating phenotype-.(YIA)
Shozo Yokoyama( Japan)
O-11 Mirtazapine postpones tumor growth and prolongs survival via overexpression of Interleukin-12 and serotonin in CT26/tk-luc tumor-bearing animal model
Chieh Y. Tung( Taiwan)
O-12 Dominance of CEACAM1 long cytoplasmic isoform is an independent risk factor for metastasis and the short survival of patients with colorectal cancer (YIA)
Junji Ieda( Japan)
O-13 EGF-conjugated liposomal doxorubicin for treatment of EGFR-overexpressing cancer (YIA)
Keng-Li Lan( Taiwan)
O-14 Differing subtypes of colorectal cancers and their precursor regions in Asia and Western countries.
Nagahide Matsubara( Japan)

O3. GIST

August. 25 Room 7 14:50 - 15:40

Chairmen: Akira SAWAKI Ishiro HONDA

O-15 Positron emission tomography can predicts the malignant potential and indication of Imatinib mesylate therapy in gastrointestinal stromal tumors
Kozo Yoshikawa( Japan)
O-16 Analysis of C-KIT gene secondary mutation and clinical significance in patients with imatinib resistant gastrointestinal stromal tumor
Zhiyu Chen( China)
O-17 Our experiences with gastric GISTs: The evaluation of risk factors.
Noritsugu Naito( Japan)
O-18 Surgical treatment for gastrointestinal stromal tumor
Toshihisa Tokumaru(Japan )
O-19 Gastrointestinal tumor-derived mesenchymal stem cells are similar to non- tumor- derived mesenchymal stem cells (YIA)
Sophie, S.W. Wang( Taiwan)

O4. Hepato-biliary tracts and pancreas 1

August. 25 Room 7 15:40 - 16:40

Chairmen: Kazuhiro TSUKADA Mitsukazu GOTO

O-20 Clinical evaluation of prognostic factors in adenocarcinoma of the ampulla of Vater
Tsutomu Kawaguchi( Japan)
O-21 Obstructive jaundice is not poor prognostic factor after curative resection of advanced gallbladder cancer.
Yuya Nasu( Japan)
O-22 Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma.
Satoshi Kuboki(Japan )
O-23 Expression of Nanog, Oct3/4, Sox2, c-Myc, and Klf4 in the human biliary tract and pancreatic cancer
Shinichi Sekine( Japan)
O-24 Phosphoglycerate kinase – 1 is a potential novel biomarker and therapy for pancreatic adenocarcinoma
Tsann-Long Hwang( Taiwan)
O-25 Indolamine 2, 3-deoxygenase (IDO) has influences for the aggressiveness of IPMN through Foxp3+CD4+CD25+Tcell (Treg) in peripheral blood
Tetsuya Ikemoto( Japan)

O5. Hepato-biliary tracts and pancreas 2

August. 25 Room 7 16:40 - 17:40

Chairmen: Hiroto EGAWA Yutaka YONEMURA

O-26 Phase I study of novel class I epitope peptide derived from tumor antigens for patients with pancreatic cancer
Nobuaki Suzuki( Japan)
O-27 Phase II study of FDR-GEM and S-1 combination therapy (FGS therapy) in GEM- refractory pancreatic cancer patients
Tomohiro Yamaguchi( Japan)
O-28 Strategy of surgical management and chemotherapy for intrahepatic Cholangio carcinoma with lymph-node metastasis
Hiroyuki Takamura( Japan)
O-29 Favorable long-term surgical outcomes of hepatocellular carcinoma in patients with hepatitis B envelope antibody
Shun-ichi Ariizumi( Japan)
O-30 Prolonged survival with multimodality therapy in the management of hepatocellular carcinoma; the current role of local ablation therapy
Kosuke Mima( Japan)
O-31 Hepatic arterial infusion chemotherapy with 5-Fluorouracil (5FU) and cisplatin (CDDP) versus 5FU and Interferon (IFN)-alpha for unresectable advanced hepatocellular carcinoma with tumor thrombus in major vessels, a randomized trial
Etsuro Hatano( Japan)

O6. Gastric cancer 5[Lymph node dissection]

August. 26 Room 8 10:00 - 11:00

Chairmen: Hiromi TANEMURA Keiichiro OHTA

O-32 Patterns of lymph node metastasis and appropriate extent of LN dissection for lower third gastric cancer according to the depth of tumor invasion
Seong-Ho Kong( Korea)
O-33 Clinical outcome of function-preserving gastrectomy using sentinel node navigation for early gastric cancer
Takashi Fujimura( Japan)
O-34 Prediction of lymph node metastasis by a novel lectin-based glycan profiling method (Lectin Microarray) in advanced gastric cancer
Keishi Yamashita( Japan)
O-35 Gastric cancer patient subgroups receiving survival benefits from lymph node dissection by splenectomy
Daisuke Ichikawa( Japan)
O-36 Factors of influenced blood loss and operation time in laparoscopic assisted distal gastrectomy
Hisae Aoki( Japan)
O-37 What should we do to improvement the prognosis of patients with advanced gastric cancer (AGC)?
Kohei Shitara( Japan)

O7. Palliative care and QOL

August. 26 Room 8 9:00 - 10:00

Chairmen: Masayuki KIMURA Ken KONDOU

O-38 Aggressive palliative care for bowel obstruction caused by carcinomatous peritonitis.
Tetsuya Kagawa( Japan)
O-39 Experiences of exploration after palliative chemotherapy for stage IV gastric cancer
Dong-Seok Han( Korea)
O-40 The QOL evaluations using SF-36 for gastric cancer patients after operation
Manabu Ohta( Japan)
O-41 Body composition change after laparoscopic and open gastrectomy
Shavkat Abdiev( Japan)
O-42 Opioid titration with transdermal fentanyl in cancer pain
Motoo Nomura( Japan)

O8. Gastric cancer 3[Multidisciplinary treatments]

August. 26 Room 7 13:30 - 14:20

Chairmen: Akihito TSUJI Yasunori EMI

O-43 Taxane-based adjuvant chemotherapy for gastric cancer patients with peritoneal dissemination
Tomoyuki Okumura( Japan)
O-44 Multidisciplinary approach including intra-peritoneal and systemic chemotherapy followed by surgery for gastric cancer with peritoneal dissemination
Yoshiyuki Fujiwara( Japan)
O-45 Continuous hyperthermic peritoneal perfusion in treating gastric cancers with peritoneal disseminations
Mao-Chih Hsieh( Taiwan)
O-46 A combination phase II study of weekly paclitaxel and doxifluridine in patients with unresectable or recurrent gastric cancer in an outpatient setting
Shigefumi Yoshino( Japan)
O-47 Pathological complete response in advanced gastric cancer Stage IV after preoperative chemotherapy including S-1 plus Cisplatin -- Report of a case
Hiroshi Funaki( Japan)

O9. Chemoradiotherapy

August. 26 Room 7 14:20 - 15:40

Chairmen: Masayuki KANEMATSU Takeo Takahashi Thinh Dang huy (Viet Nam)

O-48 Toxicities and response of concurrent chemoradiotherapy for stage IIB-IIIB cervical cancer
Dang Ngoc Linh Tran( Viet Nam)
O-49 Phase II trial of concurrent chemoradiotherapy with S-1 every other day for high risk head And neck cancer patients
Kohichi Yamauchi( Japan)
O-50 Adjuvant chemoradiotherapy after curative resection for ampulla of Vater cancer
Kyubo Kim( Korea)
O-51 Quality assurance of the KROG 08-06 study, Phase III randomized trial to investigate the role of internal mammary lymph node irradiation for breast cancer patients
Yoonsun Chung( Korea)
O-52 Radiotherapy concurrently with weekly cisplatin followed by adjuvant chemotherapy for N2-3 nasopharyngeal cancer: Prospective trial of the forum for nuclear cooperation in Asia (FNCA)
Tatsuya Ohno( Japan)
O-53 A prospective Phase II trial of hypofractionated IMRT in patients with high-risk prostate cancer
Yueping Liu( China)
O-54 Therapeutic effects and adverse events of preoperative chemoradiotherapy for rectal cancers.
Soichiro Ishihara( Japan)
O-55 Significance of preoperative chemoradiation therapy for low rectal and anal cancer
Masanori Nishioka( Japan)

O10. Cancer of the central nerve system

August. 26 Room 7 15:40 - 16:20

Chairmen: Jun SHINODA Jun YOSHIDA

O-56 Functional diffusion map : New imaging assessment of glioblastoma patients treated by boron neutron capture therapy
Ryo Hiramatsu( Japan)
O-57 Detection of somatic mitochondrial DNA mutations in different grades of human astrocytoma and its recurrence tissues
Chih Lung Lin( Taiwan)
O-58 Postoperative neurological improvement did not correlated with performance status in elderly patients with metastatic brain tumors treated surgically.
Motomasa Furuse( Japan)
O-59 Recent progress of boron neutron capture therapy (BNCT) for malignant glioma
Shinji Kawabata( Japan)

O11. Breast Cancer 1[Chemotherapy and biomarker]

August. 26 Room 7 16:20 - 17:30

Chairmen: Shinji OHNO Akira TANGOKU

O-60 Clinical efficacy of S-1 in locally advanced and metastatic breast cancer patients
Hirohito Seki( Japan)
O-61 Chemotherapy with capecitabine for advanced or metastatic breast cancer patients
Yoshihiro Kawaguchi(Japan )
O-62 E-cadherin and Ki67 might be a predictive marker for chemo-sensitivity in triple-negative breast cancer (YIA)
Shinichiro Kashiwagi( Japan)
O-63 Predictive factors for pathologic complete response following neoadjuvant chemotherapy in patients with breast cancer (YIA)
Changhoon Yoo( Korea)
O-64 Alternation of Her-2 expression by neoadjuvant chemotherapy in primary breast cancer
Tatsuto Nishigori( Japan)
O-65 Hereditary breast &/or ovarian cancers in Indian women (YIA)
Veluswami Sridevi( India)
O-66 Conservation surgery of breast cancer at Bhaktapur Cancer Hospital, Nepal (YIA)
Kapendra Shekhar Amatya( Nepal)

O12. Lung cancer

August. 26 Room 7 17:30 - 18:20

Chairmen: Nagahiro SAIJO Yi-Long Wu (China)

O-67 Novel therapeutic strategy with E7080, an orally active inhibitor of multiple receptor tyrosine kinases, for controlling experimental metastasis by lung cancer cells in immunodeficient mice (YIA)
Atsushi Mitsuhashi( Japan)
O-68 Survival determinants in patients with gefitinib-sensitive non-small cell lung cancer; is timing of gefitinib important? (YIA)
Young Joo Lee( Korea)
O-79 A randomized phase III study of a cisplatin (CDDP) and docetaxel (DOC) with or without irinotecan (CPT) in patients (pts) with advanced NSCLC: Results of Okayama Lung Cancer Study Group OLCSG 0403(YIA)
Shigeki Umemura( Japan)
O-70 A randomized phase III trial comparing docetaxel and cisplatin combination chemotherapy to mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer: OLCSG 0007(YIA)
Yoshiyuki Tokuda( Japan)
O-71 Constitutive activation of STAT family in colon and lung cancers
Takao Takahashi(Japan )

O13. Colorectal Cancer 1[Surgical approach and its out come]

August. 27 Room 7 9:00 - 10:00

Chairmen: Takeo MORI Sotaro SADAHIRO

O-72 A population-based survey on knowledge and attitude toward colorectal cancer and colorectal cancer screening among Indonesian population (YIA)
Murdani Abdullah( Indonesia)
O-73 Managing colorectal cancer: Three years review.(YIA)
Ramesh Singh Bhandari( Nepal)
O-74 The relationship of lymph node evaluation and colorectal cancer survival after curative resection: A multi-institutional study
Yukihide Kanemitsu( Japan)
O-75 Pelvic recurrence of rectal cancer: our proposal of surgical indication
Hisashi Onodera( Japan)
O-76 “Adjuvant surgery” for patients who have unresectable liver metastasis
Kenichi Nonaka(Japan )
O-77 Efficacy of adjuvant chemotherapy after surgery in colorectal cancer
Hye Ryun Kim( Korea)

O14. Colorectal Cancer 2[Chemotherapy]

August. 27 Room 7 10:00 - 11:10

Chairmen: Hideyuki MISHIMA 　　Masahiko WATANABE

O-78 Cetuximab monotherapy for patients with irinotecan intolerant metastatic colorectal cancer (MCRC)
Ayako Mizota( Japan)
O-79 Multicenter feasibility study of the Sendai Oncologist Salon (SOS) group on the adjuvant chemotherapy with a 4-week administration method of S-1 for colorectal cancer.
Koh Miura( Japan)
O-80 Efficacy and safety of cetuximab plus irinotecan as third-line therapy for metastatic colorectal cancer
Akira Tanaka( Japan)
O-81 The optimal dose period of indisetron tablets for preventing chemotherapy- induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial –HGCSG0703 (YIA)
Hiroshi Nakatsumi( Japan)
O-82 Combination of p53 polymorphism and inactive mutation predicts chemosensitivity in colorectal cancer
Toshiji Tominaga( Japan)
O-83 A retrospective analysis of the effects of multimodality therapy for locally recurrent rectal cancer
Mitsugu Sekimoto( Japan)
O-84 Predictive value of cancer stem-like cells and cancer associated genetic markers for peritoneal recurrence of colorectal cancer patients with curative surgery
Hisae Iinuma( Japan)

O15. Cancer of the bone and soft tissue

August. 27 Room 7 11:10 - 12:00

Chairmen: Katsuji SHIMIZU Hiroshi YOKOZAKI

O-85 Clinical outcome of repeated metastasectomy for pulmonary metastasis of osteosarcoma
Jin W. Hwang( Korea)
O-86 MEWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A
Akihito Nagano( Japan)
O-87 Troglitazone modulates doxorubicin drug resistance through MDR1, p53, IL8 and ECOP
THANGARAJAN RAJKUMAR( India)
O-88 Continuous intra-arterial infusion chemotherapy for osteosarcoma
Takatoshi Ohno( Japan)
O-89 Oral uracil and tegafur as a post-operative adjuvant chemotherapy in high-risk oral squamous cell carcinoma patients
Chung Ji Liu（Taiwan）

O16. Cancer of the head and neck

August. 27 Room 7 13:30 - 14:30

Chairmen: Yasuhisa HASEGAWA Keisuke MIZUTA

O-90 Mandibular reconstruction with fibula flap after segmental mandibulectomy for ameloblastoma
THAI THANH NGUYEN( Viet Nam)
O-91 Nasolabial flap reconstruction of oral cavity defects: a report of 15 cases
THANH THI VAN HAN( Viet Nam)
O-92 Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas
LONG KHANH NGUYEN( Viet Nam)
O-93 Concurrent chemoradiotherapy in locally advanced stage tonsillar carcinoma: initial response and acute toxicities (YIA)
Thu Thao L. P. Bui( Viet Nam)
O-94 The role of induction chemotherapy in treatment of local regional advanced tonsillar carcinoma (YIA)
DUC HOANG LAM( Viet Nam)
O-95 Usefulness of ultrathin transnasal endoscopic PEG in patients with severe pharyngeal stenosis due to recurring malignancies
Hirohisa Takeuchi( Japan)

O17. Patients care of Cancer

August. 27 Room 7 14:30 - 15:30

Chairmen: Takashi HIGASHIGUCHI Tomoko IZAWA

O-96 Current status and problems of team oncology for gastrointestinal cancer
Tomomi Yakabe( Japan)
O-97 Nutritional status of cancer patients admitted for chemotherapy at the National Kidney and Transplant Institute(NKTI)
Jose Enrique Y. Montoya( Philippines)
O-98 Symptoms and quality of life according to survival in hospice cancer patients
Youn Seon Choi( Korea)
O-99 Outcomes of airway stenting for advanced lung cancer with central airway (YIA)
Tatsuya Inoue( Japan)
O-100 A Ileostomy care in the ovarian cancer patient who occurred severe skin irritation.
Kinoshita Sachiko( Japan)
O-101 Analysis of risk factors for postoperative wound complications in 338 breast cancer patients (YIA)
RAJKUMAR K SEENIVASAGAM( India)

O18. Esophagus and gastric cancer

August. 27 Room 7 15:30-16:20

Chairmen: YHitoshi SHIOZAKI Soji OZAWA

O-102 Treatment strategy for adenocarcinoma of the esophagogastric junction, overview
Takaki Yoshikawa( Japan)
O-103 Adenocarcinoma of the esophagogastric junction at a Japanese high-volume cancer center (YIA)
Shinichi Hasegawa( Japan)
O-104 Folate intake associated with better outcome of patients with advanced gastric cancer treated with first-line fluorouracil based chemotherapy
Kohei Shitara( Japan)
O-105 Imaging small metastatic gastric cancer lesions using Cox2-specific replicative adenovirus
Takashi Kosaka( Japan)
O-106 Treatment of pseudomyxoma peritonei with combination of complete cytoreduction and continuous hyperthermic peritoneal perfusion
Chang Yun Lu( Taiwan)

O19. Cancer of the soft tissue and others

August. 27 Room 8 8:30 - 9:20

Chairmen: Yoshihiro KAWAGUCHI Sunil Kumar Sikder（Bangladesh）

O-107 Eight cases of medullary thyroid carcinoma. A single institution’s experience and surgical strategy in Japan.
Ichiro Akiyama( Japan)
O-108 Groin lymph node dissection in melanoma with positive sentinel lymph nodes : A Japanese multi-institutional study for melanoma
Arata Tsutsumida( Japan)
O-109 Surgical management of giant recurrent abdominal wall desmoid tumours – A case report and review of literature (YIA)
RAJKUMAR K SEENIVASAGAM( India)
O-110 Local flaps in reconstruction for skin cancer of the cheek (YIA)
Tuong, Thi Anh Tran( Viet Nam)
O-111 Novel sunitinib strategy in metastatic renal cell cancer with hemodialysis(YIA)
Hyang K Kim( Korea)

O20. Laparoscopic surgery

August. 27 Room 8 9:20 - 10:20

Chairmen: Nobuyasu KANO Norio SHIRAISHI

O-112 Laparoscopic distal pancreatectomy for benign or borderline malignant pancreatic tumors
Masayuki Ohta( Japan)
O-113 Laparoscopic left liver resection: Technical refinement for standardization of laparoscopic left hepatic lobectomy
Satoru Imura( Japan)
O-114 A phase II study of laparoscopic distal gastrectomy for clinical T1N0-1/T2N0 gastric cancer
Takaki Yoshikawa( Japan)
O-115 Clinical outcomes of laparoscopic intersphincteric resection for low rectal adenocarcinoma
Sang-Woo Lim( Korea)
O-116 The current status of laparoscopic colorectal surgery in our department.
Takao Takahashi(Japan )
O-117 Efficacy and limitation of staging laparoscopy in patients with advanced gastric cancer
Mitsuru Waragai( Japan)

21. Others

August. 27 Room 8 10:20 - 11:20

Chairmen: Toshiro KONISHI Shoji NAKAMORI

O-118 The usefulness of diffusion-weighted MR imaging for detecting gallbladder carcinoma
Kazuhiko Hashimoto( Japan)
O-119 Usefulness of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for abdominal tumors
Osamu Nakahara( Japan)
O-120 Epithelial-mesenchymal transition status and EGFR mutation in EGFR-TKI- resistant lung adenocarcinoma
Hidetaka Uramoto( Japan)
O-121 FDG-PET as a potential tool to select patients with advanced non-small cell lung cancer (NSCLC) who may spare immediate maintenance therapy after first-line chemotherapy (YIA)
Dok Hyun Yoon( Korea)
O-122 Suppression of metastatic potential of cancer by heavy ion particle irradiation
Masaru Isono( Japan)
O-123 Decompression of malignant obstruction using percutaneous transesophageal gastrostomy (PTEG) tube for patients with contraindication of surgical treatment
Hitoshi Nagata( Japan)

O22. Others and future trial

August. 27 Room 8 11:20 - 12:00

Chairmen: Bunzo NAKADA Kenji OMURA

O-124 The attempt of tailor-made chemotherapy from biopsy specimens
Keita Kai( Japan)
O-125 Clinical efficacy of Octreotide in malignant bowel obstruction
Motohiro Ito( Japan)
O-126 Use of RFP and GFP transgenic nude mice to study the tumor microenvironment of liver metastasis
Atsushi Suetsugu( USA)
O-127 Evaluation of the number of the stasion of metastatic lymph node in CT as prognosticator in gastric cancer
Yoko Motegi( Japan)

13.Poster Presentation with wine & cheese party at Royal Theater

1. Group A: August 25 from 19:00 to 21:30

2. Group B: August 26 from 17:30 to 19:00

Group A

P-A1. Esophageal cancer

Chairmen: Yutaka SHIMADA Tadashi NISHIMAKI

P-1 Clinical significance of SIP1 and E-cadherin in patients with esophageal squamous cell carcinoma
Rintaro Yoshida( Japan)
P-2 Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus
Yoshitsugu Nakanishi( Japan)
P-3 A traditional Japanese medicine (kampo) Rikkunshito is a new candidate supporting drug which improves QOL during chemotherapy with docetaxel/ 5-FU/ CDDP for advanced esophageal cancer patients
Satoshi Fujiwara( Japan)
P-4 A case of small cell esophageal carcinoma with long-term survival after curative resection without adjuvant chemotherapy
Kazuya Muguruma( Japan)
P-5 Antethoracic pedicled jejunum reconstruction with supercharge for thoracic esophageal cancer
Naoki Iwata( Japan)
P-6 Clinical result of neoadjuvant chemoradiotherapy for resectable esophageal cancer
Jun Hihara( Japan)
P-7 Clinical review of cervical lymph node dissection for thoracic esophageal squamous cell carcinoma
Hae W. Lee( Korea)
P-8 Cancer vaccine in combination with anti-CD25 antibody for advanced esophageal squamous cell carcinomas -A case of the prolonged stable disease-
Yoshiyuki YAMAGUCHI( Japan)
P-9 Evaluation of combination chemotherapy of Docetaxel, nedaplatin, and S1(DGS) for advanced esophageal carcinoma
Yoshihiro Tanaka(Japan )

P-A2. Liver cancer

Chairmen: Yoshiyuki Nakajima Motohide SHIMAZU

P-10 The serial change of therapeutic approach for hepatocellular carcinoma and improvement of long-term outcome after treatment: A single-center experience for 20 years.
Kazuki Takeishi( Japan)
P-11 Elasticity imaging of liver tissues using a scanning haptic microscopy
Ryo Okada( Japan)
P-12 Safety study of chemotherapy for the cancer patients with hepatitis virus infection
Taro Yokoyama( Japan)
P-13 Lobaplatin induces G1 and G2/M cell cycle arrests in SMMC-7721 human hepatocellular carcinoma cells
Shu kui Qin( China)
P-14 Oral Thalidomide in Patient with Hepatocellular Carcinoma: A retrospective analysis
Po-Huang Lee　（Taiwan)
P-15 Is the lymph node metastasis considered as a significant prognostic factor in intrahepatic cholangiocarcinoma?
Tomohide Nakayama( Japan)
P-16 EUS-FNA of biliary lesions
Yasuhiro Oshima( Japan)
P-17 Curative resection after down-staging chemotherapy for initially unresectable gallbladder carcinoma
Atsushi Kato(Japan )
P-18 Anti-angiogenic activity of vitamin D binding protein-macrophage activating factor
Kanako Mori( Japan)
P-19 The role of c-Met expression in colorectal liver metastasis
Toshiyuki Tanahashi(Japan )

P-A3. Biliary tract cancer

Chairmen: Toshiaki NONAMI Shinji OSADA

P-20 Preliminary phase II results of oxaliplatin, 5-FU and leucovorin in advanced biliary tract cancer
Jong-Ho Won( Korea)
P-21 14 cases of gallbladder cancer diagnosed after laparoscopic cholecystectomy
Takahito Adachi( Japan)
P-22 A case of long-term survival after resection of liver metastasis from hilar cholangiocarcinoma
Aiko Ikawa(Japan )
P-23 Mucin phenotypes of intraductal papillary-mucinous neoplasm (IPMN) of the pancreas and localization of the most severely dysplastic intraductal lesions and minimally invasive lesions
Hidenori Karasaki( Japan)
P-24 Overexpression of EGFR in the exocrine pancreas induces a chronic pancreatitis
Satoshi Ida( Japan)
P-25 Significance of lymphangiogenesis in primary tumor and draining lymph nodes during lymphatic metastasis of pancreatic head cancer
Hiroshi Kurahara( Japan)
P-26 Two cases of early pancreatic cancer
Nobuhiro Ito( Japan)
P-27 A case of metastatic pancreatic tumor from renal cell carcinoma
Masayoshi Nagahama( Japan)
P-28 Gemcitabine and S-1 combined neoadjuvant chemotherapy for patients with locally advanced pancreatic cancer
Hiroto Egawa( Japan)
P-29 Oral S-1 plus gemcitabine and concurrent radiotherapy in patients with T3-4 and M0 cancer of pancreas
Goro Honda( Japan)
P-30 Mucinous cystic neoplasm of the pancreas in a male patient
Yasuharu Tokuyama( Japan)
P-31 Increased circulating cell signaling phosphoproteins in sera are useful for the detection of pancreatic cancer.
Shigetsugu Takano(Japan )
P-32 Evaluation of the pancreatic endocrine tumors based on TNM classification
Yasuo Sakamoto( Japan)
P-33 　Immunohistochemical Study of Claudin 18 Involvement in Intestinal Differentiation During the Progression of Intraductal Papillary Mucinous Neoplasm
Yuichi Sanada(Japan)

P-A4. Cancer of the stomach 1

Chairmen: Kyoji OGOSHI Toshio TAKAHASHI

P-34 Quantitative COX2 promoter methylation analysis in gastric carcinoma
Jae Kyoon Joo( Korea)
P-35 Annexin A1 expression analysis in gastric and colon cancer and its clinical significance
Yu Sato( Japan)
P-36 Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis
Takaaki Arigami( Japan)
P-37 Ectopic expression of MECA-79 as a novel prognostic indicator in gastric
Hirokazu Okayama( Japan)
P-38 Bone marrow and peripheral blood expression of ID1 in human gastric carcinoma patients is a bona fide indicator of lymph node and peritoneal metastasis
Masaaki Iwatsuki( Japan)
P-39 Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells.
Kyung Hee Lee( Korea)
P-40 Outcome of salvage surgery for unresectable gastric cancer after down staging of non-curative factors by chemotherapy
Haruhiko Cho( Japan)
P-41 A case of adenosquamous carcinoma of stomach
Haruyoshi Tanaka( Japan)
P-42 Evaluation of the reduction surgery according to the type of surgery for incurable advanced gastric cancer
Teiji Naka( Japan))
P-43 Comparison of reconstruction in laparoscopic distal gastrectomy
Atsushi Kawabe( Japan)

P-A5. Cancer of the stomach 2

Chairmen: Kaoru MIYASHITA Naoki HIRABAYASHI

P-44 Single incision surgery for gastric tumors
Nobuyuki Shimizu( Japan)
P-45 Therapeutic outcome and prognosis in S-1+CDDP chemotherapy for advanced gastric cancer:Postoperative histopathological sssessment
Kaori Tanaka( Japan)
P-46 Effectiveness of TS-1 + Paclitaxel for gastric cancer with peritoneal metastasis
Kazunori Yawata( Japan)
P-47 S-1 alone versus S-1 plus cisplatin for curability C (P1 or CY1) post operative advanced gastric cancer
Kentaro Yamaguchi( Japan)
P-48 A combination chemotherapy with Oxaliplatin, 5-fluorouracil, and leucovorin (mFOLFOX) as first-line treatment in advanced gastric cancer (AGC)
Jina Yun( Korea)
P-49 The feasibility and efficacy of combination chemotherapy with paclitaxel and S-1 for advanced gastric cancer
Takashi Mine( Japan)
P-50 Three cases of gastric cancer with para-aortic lymph node metastases Succesfully treated by TS-1/CDDP combination therapy followed by curative resection
Tanaka Chihiro( Japan)
P-51 Clinical course of patients with non-curative gastric cancer in a community-based hospital
Hyoun jong Moon( Korea)
P-52 Clinical evaluation of SEMS (self-expandable metallic stent) for gastric cancer : Assessment of QOL(quality of life).
Sugiyama Akihiko( Japan)
P-53 Impact of adoptive T cell therapy on the cytokines production and the number of Treg in peripheral blood of patients with cancer
Takeshi Ishikawa( Japan)
P-54 Clinicopathological characteristics of lymphepithelioma-like gastric carcinoma
Yoichi Sugiyama(Japan )

P-A6. Cancer of the stomach 3

Chairmen: Takeo KOSAKA Yoshiaki IWASAKI

P-55 PET diagnosis for lymph node metastasis of gastrointestinal cancer
Kenji Kawashima( Japan)
P-56 SUVmax of F-18 FDG-PET/CT in advanced gastric cancer with tubular adenocarcinoma: Correlation with pathologic findings including immuno- histochemical staining
Jin Young Kim( Korea)
P-57 Usefulness of preoperative F-18 FDG-PET/CT for detection of signet ring cell carcinoma of stomach: Relating to pathologic findings including immuno- histochemical Staining
Keon Uk Park( Korea)
P-58 Interrupted healing of leakage from gastroduodenostomy after radical gastrectomy for gastric cancer, caused by anti-adhesive film
Hyoun jong Moon( Korea)
P-59 Efficacy of oncolytic reovirus against peritoneal metastasis in gastric cancer
Koji Kawaguchi( Japan)
P-60 Docetaxel, oxaliplatin, and S-1 combination chemotherapy in metastatic gastric cancer: results of a phase II study
Dae Young Zang( Korea)
P-61 Combination therapy with docetaxel and S-1 in patients with advanced gastric cancer: A single-institution retrospective study
Kazuaki Tanabe( Japan)
P-62 S-1 mono-therapy every 3 weeks as first-line salvage treatment in untreated elderly patients with recurrent or metastatic gastric cancer
Joo Han Lim( Korea)
P-63 Feasibility of adjuvant S-1 plus docetaxel against stage II-III gastric cancer following R0 resection in gastrectomy
Yasunori Emi( Japan)
P-64 Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection
Seok Y Kang( Korea)

P-A7. Cancer of the stomach 4

Chairmen: Katsuyuki KUNIEDA Takashi FUJIMURA

P-65 Impact of metabolic syndrome on gastric dysplasia in a general Korean population
Hyun Young Kim( Japan)
P-66 Clinicopathologic characteristics of the carcinoma in the remnant stomach after distal gastrectomy
Makoto Yamada( Japan)
P-67 Prognostic significance of Aquaporin (AQP) expression in gastric and colorectal cancer
Soshi Osawa( Japan)
P-68 MicroRNA-196b and microRNA-363 were identified as gastric cancer specific Micro RNAs in human gastric cancer tissue using microarray experiment
Jae Yun Lim( Korea)
P-69 High expression of atypical protein kinase C λ/ι in gastric cancer as a prognostic factor for recurrence
Ryo Takagawa( Japan)
P-70 P-glycoprotein plays a critical role in cross-resistance of 5-Fu and Paclitaxel
Ryutaro Mori(Japan )
P-71 Single center experience of chemotherapy combined with surgery for Stage IV gastric cancer
Sanae Nakajima( Japan)
P-72 Clinical outcomes of laparoscopy-assisted proximal gastrectomy (LAPG) with narrow gastric tube reconstruction
Norio Shiraishi( Japan)
P-73 Sunitinib as a second line therapy for advanced GISTs after failure of imatinib in Korean patients
Min-Hee Ryu( Korea)
P-74 A resected case of effective treatment with S-1 + CPT-11 combination chemotherapy for advanced Gastric cancer
Shimpei Kawaguchi( Japan)
P-75 Treatment for patients with cytology positive and/or peritoneal dissemination from gastric cancer in our hospital
Masahiro Gotoh( Japan)

P-A8. Cancer of the stomach 5

Chairmen: Naoki OKUMURA Akira TSUBURAYA

P-76 A randomized phase II study of irinotecan monotherapy versus irinotecan plus 5-fluorouracil/leucovorin combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer
Sun Jin Sym( Korea)
P-77 Usefulness of postoperative management based on ERAS of patients with gastrectomy
Noriko Yoshimura(Japan )
P-78 Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy
Young-Iee Park( Korea)
P-79 Assessment of quality of life after gastrectomy for gastric cancer depending on the differences in surgical approaches and reconstruction methods
Daisuke Kobayashi( Japan)
P-80 Novel peristaltic aboral pouch at Roux-en-Y limb after total gastrectomy
Kuniaki Aridome( Japan)
P-81 Narrow band imaging during staging laparoscopy for the diagnosis of peritoneal metastasis due to advanced gastric cancer
Kinji Kamiya( Japan)
P-82 S-1 plus Oxaliplatin(SOX) as neoadjuvant chemotherapy for local advanced gastric cancer: Report of a case
Jiafu Ji( China)
P-83 A pilot study of S-1 plus oxaliplatin as neoadjuvant chemotherapy for highly advanced gastric carcinoma
Jiren Yu( China)
P-84 Retrospective analysis of S-1 combined with oxaliplatin (SOX) as neoadjuvant chemotherapy for advanced gastric cancer: the result of safety and efficacy.
Lin Chen( China)
P-85 A safety analysis of S-1/nab-Paclitaxel (ABRAXANE) for the patients with unresectable or recurrent gastric cancer
Jia Chen( China)
P-86 Laparoscopic gastrectomy for early gastric cancer
Kazuhiko Omote( Japan)
P-87 Evaluation of laparoscopic gastrectomy in 190 patients
Kazuya Yamaguchi(Japan )

P-A9. Cancer of the stomach 6

Chairmen: Yutaka TAKAHASHI Kannika Phornphutkul (Thailand)

P-88 Kinetic data concerning insertion of bladeless trocar at real surgery for development of virtual training system for initial trocar placement in laparoscopic surgery
Takuya Watanabe( Japan)
P-89 Evaluation of the prognostic factors for non-curative gastric cancer
Kuwabara Kouki( Japan)
P-90 The antitumor effect and action mechanism of lapatinib for HER2 over expressing gastric cancer cell lines
Yukiko Oshima( Japan)
P-91 A disseminated intravascular coagulation at presentation of advanced gastric cancer
In Gyu Hwang( Korea)
P-92 The second line chemotherapy in Japanese advanced or recurrent gastric cancer patients – Relationship between the number of regimens and
Tetsuya Kusumoto( Japan)
P-93 Expression of N-acetylglucosaminytransferase V is associated with poor prognosisin gastric cancer
Ibu Matsuzaki( Japan)
P-94 Can nutritional factors predict poor prognosis in curatively resected gastric cancer patients?
Takeo Kosaka( Japan)
P-95 E-cadherin methylation in normal mucosa precedes diffuse type gastric carcinoma
Chan Yong Park( Korea)
P-96 Reconstruction method after laparoscopic gastrectomy
Shinichiro Mizui(Japan )

P-A10. Colorectal cancer 1

Chairmen: Keiichi TAKAHASHI Takao TAKAHASHI

P-97 Examination of LAT1 appearance in colon cancer
Suguru Hayase( Japan)
P-98 UHRF1 expression was up-regulated and associated with cellular proliferation in colon cancer
Yasuhide Kofunato( Japan)
P-99 Aberrant methylation of heparan sulfate glucosamine 3-O-sulfotransferase 2genes as a biomarker for early detection in colorectal cancer
Shiro Saito(Japan )
P-100 A clinicopathological study of 21 cases with necrotizing obstructive colitis- a fulminant complication of obstructing colorectal cancer
Koji Shibata( Japan)
P-101 Gastrocolic fistula secondary to adenocarcinoma of the colon: Case report and review of the literature
Hisashi Imai( Japan)
P-102 Study of the curative resection for colon cancer in stage 0 and I as via a minilaparotomy approach.
Yusuke Tajima( Japan)
P-103 Relationship between the size and metastasis of hepatic lymph nodes in patients with synchronous liver metastasis of colorectal cancer.
Yusuke Tajima( Japan)
P-104 Adjuvant chemotherapy on hepatectomy for liver metastases from colorectal cancer
Masaki Sunagawa( Japan)
P-105 A retrospective study of laparoscopic surgery for colorectal cancer in our clinic
Shinji Nakashima( Japan)
P-106 Surgically treated tumors of small bowel
Nobuhiro Morioka( Japan)

P-A11. Colorectal cancer 2

Chairmen: Masatoshi ISOGAI Tomohisa FURUHATA

P-107 Clinicopathologic factors for predicting early tumor recurrence in the remnant liver after simultaneous liver resection for synchronous colorectal liver metastasis
Shintaro Kuroda( Japan)
P-108 Irinotecan/ S-1 (IRIS) therapy for oxaliplatin-resistant metastatic colorectal cancer
Kenji Ina( Japan)
P-109 Two cases of unresectable colorectal cancer with long-term survival treated by UFT / CPT-11
Takeo Sato( Japan)
P-110 Significance of hepatic lymph node metastasis in patients with synchronous unresectable liver metastasis of colorectal cancer
Emi Miura( Japan)
P-111 Capecitabine- monotherapy as salvage treatment after failure of FOLFOX and FOLFIRI in metastatic colon cancer
Seung T Kim( Korea)
P-112 Phase I/II study of S-1/LV plus oxaliplatin (SOL) for untreated metastatic colorectal cancer: Final report of the phase I part.
Kentaro Yamazaki( Japan)
P-113 Polymorphisms of GSTP1, GSTT1, GSTM1, MTHFR, TS, ERCC1 and ERCC2 in metastatic colorectal cancer treated by first line mFOLFOX6 chemotherapys
Keiichiro Ishibashi( Japan)
P-114 Examination of utility in patients with KRAS status of advanced colorectal cancer treated with Cetuximab
Takayuki Kii( Japan)
P-115 KRAS / BRAF gene mutation and response to treatment with cetuximab in metastatic colorectal cancer
Konosuke Moritani( Japan)
P-116 Prediction of effects from chemoradiotherapy for rectal cancer using biopsy specimen before and one week after the start of chemoradiotherapy
Toshiyuki Suzuki( Japan)

P-A12. Colorectal cancer 3

Chairmen: Akio YAMAGUCHI Ryoji KATO

P-117 Quality of life of colorectal cancer stoma patients at the Cancer Institute, Philippine General Hospital
Sherry Athena D. Ruste( Philippines)
P-118 Approach for promoting clinical trials by the Multicenter Clinical Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group led by Osaka University
Tsunekazu Mizushima( Japan)
P-119 Appropriate postoperative surveillance system based on clinical outcome
Kazuhide Yonaga( Japan)
P-120 CITED1 protein expression level can predict lymph node metastasis in T1 colorectal cancer.
Toru Nasu( Japan)
P-121 Are NCCN and ESMO guidelines appropriate for the management of stage II colon cancer?
Satoshi Hatano( Japan)
P-122 Prediction of lateral lymph node metastasis by magnetic resonance imaging
Satoshi Hatano( Japan)
P-123 The therapeutic strategies of familial adenomatous polyposis based on molecular genetic testing
Hidekazu Sugeno( Japan)
P-124 A case of advanced colon cancer with metastases to both supraclavicular and para-aortic lymph nodes effectively treated by radiation and S-1 therapy
Yoshiyuki Sasaki( Japan)
P-125 Expanded nursing role of supportive care for postoperative gastrointestinal cancer patients in outpatient departments
Michie Asano( Japan)
P-126 Expression of ABCD1 in human colorectal cancer.
Kotaro Miyamoto( Japan)

P-A13. Colorectal cancer 4

Chairmen: Yukihide KANEMITSU Shingo KAMEOKA

P-127 An analysis of surgical outcomes in oncologic emergencies
Masayoshi Nagahama( Japan)
P-128 Perioperative blood transfusion and prognosis in colorectal cancer
Taisuke Otani( Japan)
P-129 Colorectal surgery with or without mechanical bowel preparation
Eiji Noda( Japan)
P-130 Analysis of the situation in laparoscopic lymph node dissection for colorectal cancer
Kazuhito Minami( Japan)
P-131 The correlation between protein expression of 5-FU metabolic enzyme (OPRT, TS, DPD) and clinicopathological feature in colorectal cancer
Shuji Komori( Japan)
P-132 Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer
Gakuji Osawa( Japan)
P-133 Experience with Bevacizumab for the treatment of metastatic colorectal cancer
Soo Hong Kim( Korea)
P-134 Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6
Junko Tamura( Japan)
P-135 Inhibition of Wnt/β-catenin signaling pathway and apoptotic cell death induced by an active fraction (HS7) from Taiwan of ungus camphoratus in human colon cancer cells
Chien-Ming Chen( Taiwan)
P-136 Prognostic impact of microRNA-related genes polymorphisms on survival of patients with colorectal cancer.
Jong Gwang Kim( Korea)

P-A14. Colorectal cancer 5

Chairmen: Yutaka OGATA Kazuhiko YOSHIMATSU

P-137 Individualized simulation using virtual reality image facilitates laparoscopic left colectomy
chie tanaka( Japan)
P-138 Review of patients treated at our hospital with a pyrimidine fluoride anti-neoplastic drug and warfarin
Nobuhisa Matsuhashi( Japan)
P-139 Clinical experiences of UDP-glucuronosyltransferase 1A polymorphisms on toxicities and treatment outcomes in Taiwanese patients treated with first line irinotecan-based regimens
Jy-Ming Chiang( Taiwan)
P-140 p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer
Goro Nakayama( Japan)
P-141 Pattern of recurrence and prognosis in patients with stage II/III colon cancer treated via the minilaparotomy approach
Kuwabara Kouki( Japan)
P-142 The clinical outcome of hepatectomy for colorectal liver metastasis after FOLFOX chemotherapy
Satoshi Matsui( Japan)
P-143 Effect of aged garlic extract on prevention of gastrointestinal cancer
Maki Takeda( Japan)
P-144 Implication of CEA shedding in colorectal cancer metastasis
Cong Shao( Japan)
P-145 Combination chemotherapy with irinotecan and oral uracil-tegafur for recurrent or metastatic colorectal cancer-Result of different regimens
Tzu-Chi Hsu　（Taiwan）

Group B

P-B15. Central nervous system

Chairmen: Hirohito YANO Renindra Aman (Indonesia)

P-146 Clinical results of Temozolomide in elderly patients with glioblastoma
Yoko Takekita( Japan)
P-147 Hypo-fractionated high-dose irradiation using IMRT planned by methionine PET for the treatment of glioblastoma multiforme
Kazuhiro Miwa( Japan)
P-148 Association of stem cell marker CD133 expression with dissemination of malignant gliomas
Atsushi Sato( Japan)
P-149 Effect of DNMT (DNA methyltransferase) inhibitors on radiosensitivity and mechanisms in U373MG cell line
Hak Jae Kim( Korea)
P-150 Influencing factors on the response of high dose methotrexate-based combination chemotherapy for primary central nervous system lymphoma
Young-Zoon Kim( Korea)
P-151 CDA-2 inhibits growth of C6 glioma cells accompanied with down regulation of DNA methyltransferase 1 and inhibition of platelet-derived growth factor receptor and Akt/PKB signaling
Gi-Ming Lai( Taiwan)
P-152 Identification of predictive factors in the radiosensitivity of glioma cells: special focus on angiogenesis, proliferation and apoptosis as tumor biological behaviours
Renindra, A Aman( Indonesia)
P-153 Stereotactic radiosurgery for brain tumors: result of experience at Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Angela Giselvania (Indonesia)

P-B16. Cancer of the head and neck

Chairmen: Akira　HARA Makoto TAHARA

P-154 Investigation coating HB(C6F5)2 and ClB(C6F5)2 branches in cancer drugs with BNCT(Boron Neutron Capture Therapy)method and determining absorb dose of branches
Majid Zarezadeh( Iran)
P-155 Feasibility of predesigned end of life (EOL) discussion as routine care in advanced cancer patients: results of a pilot study.
Sun Gu Kim( Korea)
P-156 Clinicopathologic examination of the follicular carcinoma of thyroid
Katsuhisa Enomoto( Japan)
P-157 Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma
Yukiyoshi Fujita( Japan)
P-158 RANKL expression is related to the treatment outcome of patients with localized, high-grade osteosarcoma
Jun Ah Lee( Korea)
P-159 A case with postoperative bone metastasis of gastrointestinal stromal tumor(GIST) expressing exon 8 mutation of KIT
Masahiro Yamamura( Japan)
P-160 Thymic hyperplasia following treatment for sarcoma
Chi Young Park( Korea)

P-B17. Hematological malignancy

Chairmen:Colonel Naeem Naqi (Pakistan) Takeshi HARA

P-161 Tryptophan catabolism has an influence on clinical outcome of the patients with diffuse large B cell lymphoma
Soranobu Ninomiya( Japan)
P-162 Treatment outcome of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for B-NHL and B-ALL in childhood
Naoto Fujita( Japan)
P-163 Clinical significance of double-balloon enteroscopy for patients with malignant lymphoma
Takashi Ibuka( Japan)
P-164 Treatment for the patients with multiple myeloma complicated by renal failure by thalidomide-based regimens
Young Mi Seol( Korea)
P-165 Two cases of CD33 positive blastic plasmacytoid dendritic cell neoplasm
Toshiki Yamada( Japan)
P-166 Search for meaning of the illness and treatment of recurrent malignancy lymphoma
mitsuki kariya( Japan)
P-167 Selectively induction of apoptosis by cordycepin via ROS generation in human leukemia cells
Jeong JinWoo(Japan )

P-B18. Urological cancer

Chairmen: Akihiro KAWAUCHI Satoshi ISHIHARA

P-168 Community-based prostate cancer screening in Japan: Predicting factors for positive repeat biopsy
Koji Okihara( Japan)
P-169 APAF-1 down-regulation reduces cell proliferation rate in testicular germ cell tumor cell lines
Reza Behjati( Japan)
P-170 Analysis of non-invasive bladder cancer which develops after bladder-preserving therapy for invasive bladder cancer
Mizuki Onozawa( Japan)
P-171 Clinical evaluation of paclitaxel and nedaplatin for second-line treatment of advanced urothelial cancer
Kazuya Mikami( Japan)
P-172 Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma – Before the molecular targeting therapy Era-
Tatsuya Takayama( Japan)
P-173 Clinical outcomes of advanced germ cell tumors assessed by IGCCC at Japanese experienced three centers
Terukazu Nakamura( Japan)

P-B19. Gynecological cancer

Chairmen: Ken-ichirou MORISHIGE Yasuhiro UDAGAWA

P-174 Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia
Shin Nishio( Japan)
P-175 Perineural ivasion in the parametrium as a prognostic factor for early-stage cervical cancer
Soyi Lim( Korea)
P-176 Systematic nerve-sparing radical hysterectomy for uterine cervical cancer : a surgical technique in Iwate Medical University
Seisuke Kumagai( Japan)
P-177 A phase II trial of combination chemotherapy with irinotecan plus oral etoposide for recurrent ovarian cancer: TGCU (Tohoku Gynecologic Cancer Nnit) 101 study
Tadahiro Shoji( Japan)
P-178 DNA damage detected with γH2AX induced by anticancer drugs on ovarian clear cell carcinoma
Eriko Takatori( Japan)
P-179 Detection with PET/CT of lymph node metastasis in patients with early-stage cervical cancer
Kwang-Beom Lee( Korea)
P-180 Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in east and south-east Asia
Shingo Kato( Japan)
P-181 Concurrent chemoradiotherapy with intracavitary radiotherapy for the patients with uterine cervical cancer to minimize the toxicity
Eun-Kee Song( Korea)
P-182 The importance of maximal cytoreductive effort in early müllerian cancer
Myong Cheol Lim( Korea)
P-183 Angiomyofibroblastoma of the vulva : case report
Yasuhiro Yokoyama( Japan)
P-184 Expression on CA9, VEGF AND SPF as biological behavior of locally advance cervical cancer
Sri, M Sekarutami( Indonesia)
P-185 Evaluation of Nimotuzumab (h-R3 Mab) combined with radiotherapy in the treatment of patients with stage III cervical cancers
Arie Munanda( Indonesia)
P-186 Characteristics of laboratory findings in cervical cancer patients in Cipto Mangunkusumo Hospital
Hendy Krisyanto( Indonesia)

P-B20. Endocrine cancer and others

Chairmen: Tomoyuki GOYA Kensei Yamaguchi

P-187 Expressions of somatostatin receptor subtypes 2a and 5 in endocrine pancreatic tumors
Ryosuke Amano( Japan)
P-188 Olanzapine as an antiemetic in refractory nausea and vomiting, anorexia in advanced pancreatic cancer
Kazuteru Komuro( Japan)
P-189 A case report of anaplastic thyroid cancer with rhabdoid feature.
Keiichi Nakano( Japan)
P-190 The consciousness structure of a patient with cancer in order to have hope in life
Yukiko Ueda( Japan)
P-191 Statistical survey of extramammary Paget’s disease based on proposal clinico- pathological TNM classification & staging and examination of treatments for advanced cases
Hideki Kamiya( Japan)
P-192 Sedatives to terminal cancer patients in the hospice ward- A sigle center experience
Hoon Kyo Kim( Korea)
P-193 The direct binding of fibroblast growth factor-1 (FGF1) to integrins is involved in FGF1 signaling
Seiji Mori( Japan)
P-194 MT2-MMP expression induces progression in cancer cells
Emiko Ito( Japan)
P-195 Inhibition of angiogenesis by heavy ion particle irradiation
Takahiro Tsuchiya( Japan)
P-196 Treatment acceptability study of hyperthermia derived from patients’ background: A retrospective analysis
Naoyuki Sakamoto( Japan)
P-197 Analysing present situation of ambulatory chemotherapy nursing in Japanese rural district
Tetsuya Isaji( Japan)
P-198 Outpatient chemotherapy in which surgeon participate
Jiro Kawakami( Japan)
P-199 The experience of cancer paitients undergoing palliative radiotherapy regarding their decision on treatment
Michiko Funahashi( Japan)

P-B21. Breast cancer 1

Chairmen: Kenichi　SAKURAI Tetsuya TAGUCHI

P-200 Combined effect of toremifene and paclitaxel in metastatic breast cancer patients
Kenichi Sakurai( Japan)
P-201 Dual cytotoxic and demethylating effects of phenethyl isothiocyanate (PEITC) in estrogen receptor-negative breast cancer cell lines
Sing Huang Tan( Singapore)
P-202 Expression of secretory leukocyte protease inhibitor in human
Sayaka Yoshida( Japan)
P-203 Evaluation of follow-up strategies for corticosteroid therapy of idiopathic granulomatous mastitis
Kenichi Sakurai( Japan)
P-204 Breast cancer at the site of an implanted pacemaker generator
Kenichi Sakurai( Japan)
P-205 Topographic diagnosis of parathyroid adenoma by imaging modalities
Kenichi Sakurai( Japan)
P-206 Combinated diagnosis of 3- dimensional computed tomography and 3- dimensional computed tomography lymphography , and 3-dimensional virtual navigation biopsy of sentinel lymph node in patients with early breast cancer
Mahito Funakoshi( Japan)
P-207 Investigation of menstruation recovery after chemotherapy and endocrine therapy for premenopausal patients with breast cancer
Kenichi Sakurai( Japan)
P-208 Is to investigate gene expression of 5-FU related enzyme in breast carcinoma useful as predictive factor of 5-FU?
Kenichi Sakurai( Japan)
P-209 Significant survival improvement of patients with recurrent breast cancer after introduction of third generation aromatase inhibitors and trastuzumab is related to HR and HER-2 status
Kimihiro Tanaka( Japan)

P-B22. Breast cancer 2

Chairmen: Shinzaburo NOGUCHI Tadao SHIMIZU

P-210 EC followed by weekly paclitaxel with/without trastuzumab as neoadjuvant chemotherapy in locally advanced breast cancer
Akira Hirano( Japan)
P-211 Preoperative chemotherapy FEC100 followed by weekly paclitaxel for locally advanced breast cancer
Hidemi Kawajiri( Japan)
P-212 A Phase II study of docetaxel in combination with epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer-analysis of response factors
Jacqueline Ming Liu　（Taiwan）
P-213 Arm edema occurred frequently in patients with axillary dissection by TC (Docetaxel and Cyclophosphamide) therapy in the adjuvant setting compared with patients with only sentinel node biopsy
Shin Takayama( Japan)
P-214 Predictors of 4 or more positive axillary nodes in patients with node-positive T1-2 breast carcinoma: the indications for adjuvant irradiation of the level III axilla and supuraclavicular fossa
Jong Hoon Lee( Korea)
P-215 QOL of terminal patients with cancer in PCUs compared to that while they were in general units
Yoshikiyo Nagai( Japan)
P-216 Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer
Kenichi Sakurai( Japan)
P-217 Breast carcinoma with osteoclast-like giant cells diagnosed by fine-needle aspiration biopsy
Kenichi Sakurai( Japan)
P-218 Study about the diagnosis ability of the axillary lymph node metastasis of the breast cancer of preoperative FDG-PET/CT on performing sentinel lymph node biopsy
Fumio Sakashita( Japan)
P-219 Characteristics of postmenopausal Japanese breast cancer patients receiving hormone replacement therapy (HRT)
Kei Kimizuka( Japan)
P-220 Correlation between immunohistochemistry and fluorescence in situ hybridization for HER-2 in primary breast cancer.
Terumasa Sawada ( Japan)

P-B23. Breast cancer 3

Chairmen: Hiroji IWATA Boon C Goh (Singapore)

P-221 Changes in bone density and bone turnover markers after anastrozole treatment and effects of bone pharmacotherapy in postmenopausal breast cancer
Akihiko Osaki( Japan)
P-222 Development of the breast disease detector used by hardness sensor (tactile sensor)
Taisuke Ito( Japan)
P-223 The experience of cancer patients undergoing outpatient radiotherapy during the period from their decision on to the initiation of treatment
Kyoko Okamitsu( Japan)
P-224 Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy
Benjamin YS Chuah( Singapore)
P-225 Expression of androgen receptor in triple negative breast cancer.
Tetsuyo Maeda( Japan)
P-226 The characteristic morphology of invasive micropapillary carcinoma of the breast: An immunohistochemical study
Rin Yamaguchi( Japan)
P-227 BORIS, a paralogue of CTCF, regulates the cellular cycle through cyclinD1 expression
Tomomi Sato( Japan)
P-228 Expression of Metadherin mRNA in peripheral blood of breast cancer patients and its clinical significance
Bing Li( China)
P-229 "Moving window" operation for breast-conserving surgery
Masafumi Inokuchi( Japan)
P-230 Relationship between hand-foot syndrome (HFS) and efficacy of capecitabine (X) alone or in combination for metastatic breast cancer (MBC)
Tetsuya Taguchi( Japan)

P-B24. Breast cancer 4

Chairmen: Arkom Cheirsilpa Kouichi SAKAGUCHI

P-231 Primary systemic therapy (PST) for advanced breast cancer
Kazuhiro Ishihara( Japan)
P-232 Field -in-field technique in breast cancer with breast conserving treatment
Ulinta Pasaribu( Indonesia)
P-233 Clinical usefulness of the high sensitive measurement of serum estradiol for endocrine therapy in breast cancer
Kei-Ichi Murakami( Japan)
P-234 Effect of platelet derived growth factor on development and progression of breast cancer
Yuhki Yokoyama( Japan)
P-235 Assessment of MMP-2 activity by film in situ zymography for improvement of cytological diagnosis of breast cancer
Chisato Fujita( Japan)
P-236 Evaluation of intramammary lymph node metastasis in patients with breast cancer performed sentinel lymph node biopsy
Masahito Nawa(Japan )

P-B25. Lung cancer

Chairmen: Hisashi IWATA Biing-Shiun Huang(Taiwan)

P-237 Therapeutic efficacy of TS-1 on the progression of human malignant pleural mesothelioma in severe combined immunodeficient mice
Van The Trung( Japan)
P-238 EGFR genotype as a prognostic factor in Advanced lung adenocarcinoma patients without chemotherapy or with cytotoxic chemotherapy
Yoon J Choi( Korea)
P-239 TTwo consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy
Keun-Wook Lee( Korea)
P-240 A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer
Hisatsugu Goto( Japan)
P-241 Clinical outcome of large cell neuroendocrine carcinoma of the lung to pre or post operative adjuvant chemotherapy, a single institutional report
Hisashi Saji( Japan)
P-242 A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations
TOSHIAKI OKADA( Japan)
P-243 Investigation of complementary and alternative medicine in lung cancer patients in in Tokushima University Hospital.
Momoyo Azuma( Japan)
P-244 CT-guided ultrathin bronchoscopy: bioptic approach and factors in predicting diagnosis
Fumihiro Asano( Japan)
P-245 Efficacy of gemcitabine and carboplatin for elderly patients with advanced non-small cell lung cancer and analysis of prognostic factors
Kyeong-Hyun Kim( Korea)
P-246 Implication of cadherin switching in cancer progression
Tao Yu( Japan)
P-247 The role of ADAM9 in brain metastasis of non-small cell lung cancer
Ayako Uchinaka( Japan)
P-248 Mechanisms of radiation resistance acquired by frequent X-ray irradiation in cancer cell line
Katsutoshi Sato( Japan)
P-249 Effects of novel radiosensitizer 2-nitoroimidazole acetamide derivatives on radiation therapy for non-small-cell lung cancer
Kazumasa Minami( Japan)